VacCiencia

FINLAY EDICIONES

Boletín Científico

No. 14 (17-30 junio / 2023)

EN ESTE NÚMERO

VacCiencia es una publicación dirigida a investigadores y especialistas dedicados a la vacunología y temas afines, con el objetivo de serle útil. Usted puede realizar sugerencias sobre los contenidos y de esta forma crear una retroalimentación que nos permita acercarnos más a sus necesidades de información.

- Noticias más recientes en la Web sobre vacunas.
- Artículos científicos más recientes de Medline sobre vacunas covid-19.
- Patentes más recientes en Patentscope sobre vacunas.

IFV INSTITUTO FINLAY DE VACUNAS

SiViFinlay

VaCyT

CUBA

Noticias en la Web

COVID-19: Vacuna bivalente se puede recibir sin vacunación previa

18 jun. El director del Programa Ampliado de Inmunizaciones (PAI) de Paraguay, Héctor Castro, señaló que la vacuna está habilitada para todas las personas desde los 6 años en adelante y que desde la próxima semana se podrán aplicar las dosis sin importar si cuenta o no con el esquema primario anticovid.

Foto: Ministerio de Salud .

Las vacunas bivalentes son de dosis única y se aplican de forma anual, similar a las vacunas contra la influenza.

Su aplicación previene las formas graves de la enfermedad respiratoria, la internación y fallecimiento, especialmente en los grupos vulnerables y susceptibles, recordó Castro en conferencia de prensa este viernes.

En el caso de las embarazadas, habiendo cumplido 12 semanas de gestación, podrán recibir la vacuna, con indicación médica, mediante un certificado médico firmado y sellado por el profesional, de acuerdo al informe de IP.

Vacuna contra la influenza

Al igual que la vacuna contra la COVID-19, la Campaña Invierno del Ministerio de Salud aplica también dosis contra la influenza.

La vacuna cuadrivalente, que protege contra los diferentes tipos de influenza, es libre para toda la población, principalmente para quienes integran grupos de riesgo; como niños de 6 a 35 meses de edad, trabajadores de la salud, embarazadas, puérperas, personas con enfermedad de base, mayores de 60 años y más.

Fuente: RDN. Disponible en https://cutt.ly/Bwuiik0l

Update on Antigen Design for Universal Sarbecovirus Vaccine by Shionogi and KOTAI

Jun 19. Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") and KOTAI Biotechnologies, Inc. (Head Office: Osaka, Japan; Chief Executive Officer: Kazuo Yamashita, Ph.D.; hereafter "KOTAI") announced meeting the criteria set in advance for the companies' joint research effort to create a Universal Sarbecovirus Vaccine that can induce neutralizing antibodies against a wide range of sarbecovirus strains and variants. SARS-CoV-2 and SARS coronavirus belong to the subgenus Sarbecovirus.

The Universal Sarbecovirus Vaccine antigen is designed to selectively induce neutralizing antibodies against regions where viral mutations are unlikely to occur and which are conserved across coronaviruses. This vaccine is expected to help to prepare for future potential COVID-19 (SARS-CoV-2) mutant variants and

potential new coronavirus pandemics, avoiding the need to continually develop new vaccines against continually evolving and emerging coronavirus mutant variants.

Under the terms of the collaboration agreement, KOTAI will receive a milestone from Shionogi for the identification of an antigen meeting the predefined success criteria for the ability to induce neutralizing antibodies across a breadth of coronavirus virus variants and strains. This collaboration has been funded and included2 in the vaccine / new modality research and development project, as part of a public solicitation by Strategic Center of Biomedical Advanced Vaccine Research and Development for Preparedness and Response (SCARDA) established within Japan Agency for Medical Research and Development (AMED).

Shionogi and KOTAI will continue to progress the research and development of a Universal Sarbecovirus Vaccine, with the support of SCARDA, to seek to bring this important advancement to patients around the world rapidly, through the synergistic combination of Shionogi's expertise in infectious diseases with KOTAI's capabilities in the analysis of immunity and protein structure using information technology.

About SCARDA

SCARDA is an organization established within the Japan Agency for Medical Research and Development (AMED) in March 2022. Based on the "Vaccine Development / Production System Strengthening Strategy" decided by the Cabinet in June 2021, it was organized for the purpose of strengthening the R&D / production system during normal times so it will be ready in times of pandemic emergency. AMED boosts the funding capacity for strategically significant research, initiative for world-leading vaccine research and development centers and promotes the strengthening of the pharmaceutical startup ecosystem. Please see SCARDA website for details.

About KOTAI

KOTAI is a biotechnology company established in 2016 based on research results from Osaka University. As a group of experts in the information analysis of immunity and protein structure, KOTAI conducts research and development in collaboration with many research institutes, universities and pharmaceutical companies. Please see the KOTAI website for details.

About Shionogi

Shionogi is committed to the principle "Protecting people worldwide from the threat of infectious diseases" as our key focus, and is working on the realization of total care for infectious diseases. While contributing to the safety and security of society, we will be prepared for the swift provision of therapeutic drugs and vaccines as necessary depending on the situation, such as the emergence of new variants or the future prevalence of the disease.

Fuente: Shionogi. Disponible en https://cutt.ly/FwuifAh0

Instituto Finlay de Vacunas y Universidad de Uruguay firman Memorando de Entendimiento en VacciPharma2023

20 jun. En el marco del evento internacional VacciPharma2023, el Instituto Finlay de Vacunas y el Departamento de Desarrollo Biotecnológico de la Universidad de Uruguay firmaron un Memorando de Entendimiento, con el objetivo de impulsar la cooperación entre ambas instituciones.

Los firmantes fueron, por la parte cubano el doctor Vicente Vérez Bencomo, director del IFV y José A.

Chabalgoity, director del Departamento de Desarrollo Biotecnológico de la casa de altos estudios de Uruguay.

En VacciPharma2023, delegados cubanos y extranjeros presentaron resultados y desarrollos de investigaciones, estrategias de control de la calidad y elementos tecnológicos en la producción de vacunas.

En este sentido, especialistas de Arabia Saudita, Estados Unidos, Uruguay, Argentina, Reino Unido, Alemania, España, Rusia, Suiza, Italia, India, Nicaragua y Cuba han compartido experiencias y conocimientos durante cuatro productivas jornadas.

Los firmantes fueron, por la parte cubano el doctor Vicente Verez Bencomo, director del IFV y José A. Chabalgoity, director del Departamento de Desarrollo Biotecnológico de la casa de altos estudios de Uruguay. Foto: Twitter/Instituto Finlay de Vacunas.

VacciPharma2023 se celebra cada dos años en Cuba. El evento es organizado por la Sociedad Cubana de Farmacología y empresas de BioCubaFarma. Debido a la pandemia de la COVID-19 no se realizaron las dos últimas ediciones.

De ahí que VacciPharma2023 tiene una alta relevancia para la ciencia cubana, pues permitió retomar estos espacios de intercambio científico y académico.

Fuente: Cubadebate. Disponible en http://www.cubadebate.cu/noticias/2023/06/20/instituto-finlay-de-vacunas-y-universidad-de-uruguay-firman-memorando-de-entendimiento-en-vaccipharma2023/

Icosavax announces initiation of Phase II pneumonia vaccine trial in adults

Jun 21. Icosavax has initiated a Phase II clinical trial of IVX-A12, a bivalent vaccine candidate, for the treatment of older adults with respiratory syncytial virus (RSV) and human metapneumovirus (hMPV).

IVX-A12 consists of two virus-like particle (VLP) vaccine candidates including IVX-121 and IVX-241.

The multi-centre, placebo-controlled, observer-blinded, randomised study intends to enrol nearly 250 healthy older adults aged 60 years and above to assess the immunogenicity and safety of a single dose of IVX-A12 with and without CSL Seqirus' adjuvant MF59.



A single dose of IVX-A12 includes 150µg of IVX-121 (RSV) and 150µg of IVX-241 (hMPV) that correspond to antigen content of 84µg RSV and 82µg hMPV, respectively.

Topline interim results from the trial are anticipated in the first quarter of next year.

Icosavax CEO Adam Simpson said: "The initiation of this Phase II trial for IVX-A12 marks another important milestone for Icosavax, as we advance this potential first-in-class combination vaccine candidate into mid-stage development.

"We are highly encouraged by the recent findings from the Phase I study of IVX-A12 and believe that it has the potential to address an unmet need as the first bivalent vaccine candidate against both RSV and hMPV, two of the leading causes of pneumonia in adults."

Icosavax plans to explore the potential of IVX-121 protecting against hMPV infection in a nonclinical passive transfer model using the clinical samples from the Phase II study.

A Phase IIb proof-of-concept trial to assess the efficacy (hMPV human challenge) of IVX-121, along with the durability and longer-term safety of immune response, will also be initiated based on the selection of the formulation from the Phase II study.

Fuente: Clinical Trials Arena. Disponible en https://www.clinicaltrialsarena.com/news/icosavax-phase-ii-pneumonia-adults/#catfish

Solicita Moderna a la FDA la autorización de su vacuna COVID-19 actualizada

23 jun. Moderna, Inc. (NASDAQ:MRNA), empresa biotecnológica pionera en terapias y vacunas de ARN mensajero (ARNm), anunció que ha completado el proceso de solicitud de autorización a la FDA para su vacuna actualizada COVID-19 que contiene proteínas de pico para el sublinaje XBB.1.5 del SARS-CoV-2 (ARNm-1273.815).

«La agilidad de nuestra plataforma de ARNm nos ha permitido actualizar la vacuna de mRNA (la vacuna COVID-19 de Moderna), para que se dirija a las variantes XBB con rapidez y rigor clínico», declaró Stéphane Bancel, director general de Moderna. «Llevamos meses trabajando diligentemente para conseguir un amplio suministro, con dosis listas a enviar a tiempo para la temporada de vacunación de otoño en el hemisferio norte.

Además, nuestras pruebas clínicas preliminares han demostrado que el ARNm-1273.815 es eficaz para generar una respuesta inmunitaria contra las variantes actuales del XBB que son motivo de preocupación. En los últimos tres años, la vacuna vacuna de mRNA contra COVID ha reducido sistemáticamente las hospitalizaciones y los resultados de enfermedades graves por COVID-19, por lo que invitamos a las personas a consultar con sus proveedores de atención médica sobre la posibilidad de recibir una vacuna actualizada».

La solicitud se basa en las recomendaciones de la FDA de Estados Unidos, que aconseja que las vacunas COVID-19 se actualicen a una composición monovalente XBB.1.5. Esta recomendación coincide con la de otros organismos reguladores y agencias mundiales de salud pública, que también han aconsejado una composición XBB monovalente. En la reciente reunión del Comité Consultivo de Vacunas y Productos Biológicos Relacionados (VRBPAC por sus siglas en inglés), Moderna fue la única compañía que presentó datos clínicos preliminares comparando vacunas monovalentes y bivalentes mostrando respuestas inmunitarias sólidas en humanos a través de múltiples sublíneas descendientes de XBB como XBB.1.5, XBB.1.16 y XBB.2.3.2.

El efecto adverso local más frecuente de la vacuna COVID-19 actualizada de Moderna fue el dolor en el lugar de la inyección. Las reacciones secundarias sistémicas más frecuentes incluyen dolor de cabeza, fatiga, mialgia y escalofríos.

La empresa ya se encuentra en proceso de presentar solicitudes adicionales a los organismos reguladores en todo el mundo y está preparada para suministrar las vacunas COVID-19 actualizadas a tiempo para la temporada de vacunación de otoño.

Fuente: Periódico Digital Centroamericano y del Caribe. Disponible en https://newsinamerica.com/pdcc/boletin/2023/solicita-moderna-a-la-fda-la-autorizacion-de-su-vacuna-covid-19-actualizada/

La vacuna hexavalente llegó para proteger a los niños de seis enfermedades

24 jun. Con el objetivo de fortalecer la inmunización de niños y niñas de 2, 4, 6 y 18 meses, se inició en Paraguay, la vacunación con la vacuna pediátrica hexavalente acelular. La misma reemplazará a las vacunas pentavalente y antipolio.

La nueva vacuna pediátrica protege contra seis enfermedades como la difteria, tétanos, tos ferina o tos convulsa, poliomielitis, haemophilus influenza tipo b y hepatitis B.

Con la hexavalente, se reduce el número de inyecciones que los niños deben recibir, generando menos dolor para ellos gracias a sus componentes acelulares y menos estrés para sus padres.

Esta implementación representa un paso sin precedentes para mejorar el Plan Nacional de Vacunación del Ministerio de Salud Pública y Bienestar Social (MSPBS) y reemplazará a las vacunas pentavalente y antipolio.

Esta vacuna está disponible desde hace años a nivel privado y con este gran logro, todos los niños y niñas tendrán acceso a la misma vacuna de manera gratuita en todos los centros vacunatorios habilitados por el Ministerio de Salud.

Esta iniciativa cuenta con el apoyo de la Sociedad Paraguaya de Pediatría (SPP), a través de su campaña “Vacunarse es poder”.

Fuente: RDN. Disponible en https://www.rdn.com.py/2023/06/24/la-vacuna-hexavalente-llega-para-proteger-a-los-ninos-de-paraguay/

Cuban central province applies booster vaccination against COVID-19

Jun 26. The third booster vaccination against COVID-19 in Villa Clara is advancing with the application of a dose of the Cuban drug Abdala to several risk groups such as older adults, children and pregnant women. "We are working harder on two-year-old children and those aged between 11 and 18, as well as breastfeeding mothers, and those already in the third trimester of pregnancy, because we have seen that vaccination guarantees important immunity levels for each of these periods," explained Yarelyn Matos, deputy director of the Provincial Center of Hygiene and Epidemiology in Villa Clara. The province's health authorities are also prioritizing the vaccination of people over 70 years of age, an essential aspect in Cuban territory with the highest population aging rate, while the immunization of health workers is also continuing.

So far, Villa Clara has accumulated more than 3 million doses of the third booster applied with the Abdala drug, while the vaccination of patients with delays due to convalescence continues, with the aim of increasing the number of people with complete immunization schedules.

Fuente: Cuban News Agency. Disponible en http://www.cubanews.acn.cu/science/21741-cuban-central-province-applies-booster-vaccination-against-covid-19

La vacuna contra COVID se integrará al esquema nacional de vacunación en México: el SARS-CoV-2 llegó para quedarse

28 jun. Las vacunas contra COVID-19 dejaron de ser universales, pero sí se incluirán en el esquema nacional de vacunación de manera que en México habrá dosis cada invierno, tal y como sucede con la influenza.

"Las personas no vacunadas conforman la mayoría de las defunciones observadas en las olas o picos más recientes", se lee en el informe de más de 150 páginas con la que serán las nuevas reglas para lidiar con el COVID-19 en México. A distancia de la aplicación de las primeras dosis, la Secretaría de Salud no asume que sigue vigente la protección de inmunidad que consiguieron todas las personas que recibieron vacunación contra COVID-19, así que recomienda que las vacunas sean aplicadas periódicamente.

Sin vacunas para los de prioridad baja

El nuevo plan de gestión establece que las vacunas contra SARS-CoV-2 estarán contempladas en esquemas de vacunación a partir de ahora, especialmente para grupos prioritarios. El plan prevé las recomendaciones de dosis hechas por el Grupo de Expertos en Asesoramiento Estratégico sobre Inmunización de la OMS, en donde se recomiendan aplicaciones cada 12 meses para adultos mayores y cada seis meses para el subgrupo de adultos más ancianos.

Para los casos de prioridad baja, es decir, niños y adolescentes sanos de seis meses a 17 años no habrá vacunación. "Considerando el beneficio y rentabilidad de la vacunación no se realizará la inmunización de los grupos con prioridad baja". En todo caso, la decisión final no puede ser tomada unilateralmente por Secretaría de Salud, sino que debe participar el Consejo Nacional de Vacunación, CONAVA, por sus siglas.

Todo parece indicar que México no estará incluyendo en el esquema de vacunación dosis que hayan sido creadas para variantes específicas. Basándose en las recomendaciones hechas por el panel de expertos de la OMS, en el plan se lee que "las vacunas actuales, basadas en el virus índice/ancestral, mantienen una alta efectividad vacunal contra enfermedades graves en el contexto de la variante Ómicron y sus sublinajes".

Tabla 1. Promedio semanal de casos estimados y defunciones por COVID-19, México, 2020-2023.

Año	Casos	Defunciones	Letalidad
2020	38,033	3,292	8.7%
2021	49,882	2,937	5.9%
2022	62,812	527	0.8%
*2023	17,749	133	0.7%

Curva epidémica, casos y defunciones por COVID-19, del 2020 a mayo del 2023.

Aunque la vacuna 'Patria' todavía no recibe permiso de Cofepris, el plan sí prevé que sea utilizada en grupos vulnerables. Según el documento, México invertirá en la fabricación de "dosis necesarias" para la vacunación entre 2023 y 2024.

Fuente: Xataka. Disponible en https://www.xataka.com.mx/medicina-y-salud/vacuna-covid-se-integrara-al-esquema-nacional-vacunacion-mexico-sars-cov-2-llego-para-quedarse

SK bioscience-Sanofi Announce Positive Results from Phase II Study of 21-Valent Pneumococcal Conjugate Vaccine Candidate

Jun 29. SK bioscience, an innovative vaccine and biotech company committed to promoting human health from prevention to cure, today announced positive results from its Phase II clinical trials in infants of its 21-valent pneumococcal conjugate vaccine candidate, 'GBP410' (also known as SP0202), evaluating its safety and immunogenicity.

GBP410, jointly developed by SK bioscience and Sanofi, is a pneumococcal conjugate vaccine that combines specific proteins with the polysaccharide capsule of Streptococcus pneumoniae, which causes pneumococcal diseases such as pneumonia and invasive pneumococcal disease. The pneumococcal conjugate vaccine is well known to provide the effective protection against pneumococcal infections among the pneumococcal vaccines developed to date.

Given that GBP410 includes 21 serotypes, it is anticipated to offer broader serotype coverage than the existing pneumococcal conjugate vaccines that currently dominate the global market. If successfully commercialized, GBP410 is expected to rapidly increase market share by leveraging Sanofi's marketing expertise as the industry leader in the pediatric vaccine market.

The Phase II study, which enrolled 140 toddlers aged 12 to 15 months and 712 infants aged 42 to 89 days , demonstrated comparable immunogenicity of GBP410 compared to the control vaccine, following the primary vaccination at 2, 4, and 6 months of age as well as the booster vaccination for ages of 12 to 15 months. This study was conducted in the United States, Canada, and Honduras and it commenced in May 2020.

The data also showed a well-tolerated safety profile, with comparable reactogenicity profile to the control vaccine and no vaccine-related serious adverse events. Furthermore, GBP410 did not interfere with the immunogenicity and safety profile of the co-administered recommended pediatric vaccines, such as tetanus, diphtheria, pertussis, polio, and Haemophilus influenzae type b vaccines.

Based on the positive safety and immunogenicity data from the Phase II clinical trial, SK bioscience and Sanofi plan to start Phase III in H1 2024, expecting to secure the final data in 2027.

In preparation for the commercialization of GBP410, SK bioscience intends to enter the U.S. and European markets with Sanofi by making significant investments in manufacturing facilities. The company will establish production facilities at L HOUSE, its vaccine manufacturing plant in Andong, Korea, ensuring compliance with the FDA's current Good Manufacturing Practice (cGMP) standards.

Jean-Francois Toussaint, Global Head of Vaccines R&D at Sanofi said, "We are pleased with our very productive partnership with SK bioscience as we work to raise the bar in pneumococcal disease. With an innovative carrier that breaks the glass ceiling of serotype compositions, our 21-valent pneumococcal conjugate vaccine is designed to offer expanded protection against this devastating disease. We believe that today's results offer us a strong path to Phase 3 and then to licensure."

Jaeyong Ahn, CEO of SK bioscience said, "The successful Phase II clinical trials of pneumococcal conjugate vaccine signifies that SK bioscience's technology and capability in vaccine development can deliver best in class vaccine candidates," adding, "We're so proud to collaborate with an excellent partner, Sanofi, and we continue to be committed to developing and manufacturing vaccines based on the global partnership with major pharmaceutical companies."

SK bioscience is accelerating to expand the global market through various global partnerships. The company seeks the key technologies for mRNA vaccine development under the contracts with domestic and international companies to expand its vaccine portfolio by securing next-generation vaccine platform. In May 2023, SK bioscience signed a manufacturing agreement with MSD for the next-generation Zaire Ebola vaccine candidate. In addition, the company is close to signing its first contract for the 'Glocalization' project, which transfers vaccine R&D and manufacturing capabilities to foreign countries with insufficient vaccine infrastructure.

About SK bioscience

SK bioscience is an innovative vaccine and biotech company, standing committed to global pandemic preparedness in vaccine development and manufacturing to create more equitable access to vaccines. In leveraging strengths on cutting-edge vaccine development technologies, SK bioscience has been dedicated to promoting human health from prevention to cure across the globe. Under collaborations of domestic and international governments, regulatory agencies, healthcare providers, doctors and medical experts, SK bioscience has firmly established globally certified R&D and manufacturing technologies. All of the SK colleagues are passionately committed to providing high-quality vaccines to those who need them and better public healthcare solutions.

Fuente: Cision PR Newswire. Disponible en https://www.prnewswire.com/news-releases/sk-bioscience-sanofi-announce-positive-results-from-phase-ii-study-of-21-valent-pneumococcal-conjugate-vaccine-candidate-301867294.html

Concluyó en Cienfuegos taller de Red de Vigilancia de la enfermedad neumocócica



29 jun. Científicos e investigadores del Instituto Finlay de Vacunas de conjunto con la Dirección Provincial de Salud presentaron este jueves en Cienfuegos las conclusiones del estudio de la intervención de QuimiVio, vacuna cubana multivalente contra el neumococo.

La intervención con el candidato vacunal comenzó desde el año 2017 en los 12 mil niños de cero a cinco años de todas las áreas de Salud del municipio Cienfuegos, única provincia en lograr la vacunación al 90 por ciento de sus infantes sin reportes adversos serios.

Según María Eugenia Toledo, una de las investigadoras principales, el objetivo del taller resultó evaluar el efecto temprano de la vacunación anti-neumocócica en campaña sobre la carga hospitalaria y poblacional de la enfermedad que provoca neumonía severa, meningitis y sensible infecciosa ocasionando la muerte infantil.

También destacó la importancia de la Red de Vigilancia, establecida en Santiago de Cuba, Cienfuegos y La Habana porque la enfermedad neumocócica es de la comunidad; por ello recomenzará la vacunación en Cienfuegos para rescatar y mantener los valores que sugieren una reducción significativa de la enfermedad y los ingresos hospitalarios.

Fuente: Radio Ciudad del Mar. Disponible en https://www.rcm.cu/2023/06/29/cienfuegos-enfermedad-neumococica/

VACCIMONITOR

VacciMonitor es una revista dedicada a la vacunología y temas afines como Inmunología, Adyuvantes, Infectología, Microbiología, Epidemiología, Validación, Aspectos regulatorios, entre otros. Arbitrada, de acceso abierto y bajo la Licencia *Creative Commons* está indexada en:

Síganos en redes sociales

@vaccimonitor

@finlayediciones

@finlayediciones

CUBA

Artículos científicos publicados en Medline

Filters activated: Publication date from 2023/06/16 to 2023/06/30. "COVID-19 vaccine" (Title/Abstract) 260 records.

COVID-19 Vaccine Evolution and Beyond.
Brice Y, Morgan L, Kirmani M, Kirmani M, Udeh MC. Neurosci Insights. 2023 Jun 19;18:26331055231180543. doi: 10.1177/26331055231180543. eCollection 2023. PMID: 37351483

Myocarditis post-COVID-19 vaccination.
Bansal M, Mehta A, Pandey M. Postgrad Med J. 2023 Jun 19:qgad030. doi: 10.1093/postmj/qgad030. Online ahead of print. PMID: 37334983

COVID-19 vaccine safety inquiries to the centers for disease control and prevention immunization safety office.
Miller ER, Moro PL, Shimabukuro TT, Carlock G, Davis SN, Freeborn EM, Roberts AL, Gee J, Taylor AW, Gallego R, Suragh T, Su JR. Vaccine. 2023 Jun 19;41(27):3960-3963. doi: 10.1016/j.vaccine.2023.05.054. Epub 2023 May 24. PMID: 37248099

COVID-19 Vaccine Decision-Making Among Black Pregnant and Postpartum Women.
Avorgbedor F, Gondwe KW, Aljarrah A, Bankole AO. J Racial Ethn Health Disparities. 2023 Jun 19. doi: 10.1007/s40615-023-01675-6. Online ahead of print. PMID: 37335424

Promises and challenges of mucosal COVID-19 vaccines.
Rathore APS, St John AL. Vaccine. 2023 Jun 19;41(27):4042-4049. doi: 10.1016/j.vaccine.2023.04.013. Epub 2023 Apr 10. PMID: 37045682

COVID-19 pandemic and adrenals: deep insights and implications in patients with glucocorticoid disorders.
Cozzolino A, Hasenmajer V, Newell-Price J, Isidori AM. Endocrine. 2023 Jun 20. doi: 10.1007/s12020-023-03411-w. Online ahead of print. PMID: 37338722

Role and clinical implication of autophagy in COVID-19.
Shan T, Li LY, Yang JM, Cheng Y. Virol J. 2023 Jun 16;20(1):125. doi: 10.1186/s12985-023-02069-0. PMID: 37328875

COVID-19 vaccination-related myocarditis: a Korean nationwide study.
Cho JY, Kim KH, Lee N, Cho SH, Kim SY, Kim EK, Park JH, Choi EY, Choi JO, Park H, Kim HY, Yoon HJ, Ahn Y, Jeong MH, Cho JG. Eur Heart J. 2023 Jun 25;44(24):2234-2243. doi: 10.1093/eurheartj/ehad339. PMID: 37264895

Trajectory of COVID-19 vaccine hesitancy post-vaccination and public's intention to take booster vaccines: A cross-sectional analysis.
Salman M, Mallhi TH, Khan YH, Mustafa ZU, Khan MT, Khan FU, Butt MH, Shehzadi N, Farrukh MJ, Waheed M, Azmat F, Saeed A, Mazhar SA, Ali A, Ashfaq A, Hussain K. Hum Vaccin Immunother. 2023 Jun 23:2225990. doi: 10.1080/21645515.2023.2225990. Online ahead of print. PMID: 37350298

The development of DNA vaccines against SARS-CoV-2.
Khalid K, Poh CL. Adv Med Sci. 2023 Jun 24;68(2):213-226. doi: 10.1016/j.advms.2023.05.003. Online ahead of print. PMID: 37364379

Efficacy of Vaccine Protection Against COVID-19 Virus Infection in Patients with Chronic Liver Diseases.
Cheung CKM, Law KWT, Law AWH, Law MF, Ho R, Wong SH. J Clin Transl Hepatol. 2023 Jun 28;11(3):718-735. doi: 10.14218/JCTH.2022.00339. Epub 2023 Jan 16. PMID: 36969905

Barriers and facilitators to COVID-19 vaccine uptake among Australian health professional students during the pandemic: a nationwide study.
Chen Y, Prichard R, Mason M, Tower M, Zimmerman PA, Sparke V, Layh J, Mehdi AM, Lin FF. J Public Health Policy. 2023 Jun 18. doi: 10.1057/s41271-023-00422-9. Online ahead of print. PMID: 37330562

Modifiers of COVID-19 vaccine efficacy: Results from four COVID-19 prevention network efficacy trials.
Turley CB, Tables L, Fuller T, Sanders LJ, Scott H, Moodley A, Woodward Davis A, Leav B, Miller J, Schoemaker K, Vandebosch A, Sadoff J, Woo W, Cho I, Dunkle LM, Li S, van der Laan L, Gilbert PB, Follmann D, Jaynes H, Kublin JG, Baden LR, Goepfert P, Kotloff K, Gay CL, Falsey AR, El Sahly HM, Sobieszczyk ME, Huang Y, Neuzil KM, Corey L, Grinsztejn B, Gray G, Rouphael N, Luedtke A; COVID-19 Prevention Network CoVPN. Vaccine. 2023 Jun 23:S0264-410X(23)00755-7. doi: 10.1016/j.vaccine.2023.06.066. Online ahead of print. PMID: 37385888

Prevalence of long COVID decreases for increasing COVID-19 vaccine uptake.
De Domenico M. PLOS Glob Public Health. 2023 Jun 21;3(6):e0001917. doi: 10.1371/journal.pgph.0001917. eCollection 2023. PMID: 37342998

Trends in COVID-19 Vaccine Hesitancy and Uptake among Persons Living with HIV in Washington, DC.
Castel AD, Barth S, Wilbourn BC, Horberg M, Monroe AK, Greenberg AE; DC Cohort Executive Committee; DC Cohort Executive Committee. J Acquir Immune Defic Syndr. 2023 Jun 26. doi: 10.1097/QAI.0000000000003243. Online ahead of print. PMID: 37368934

Biological mechanisms underpinning the development of long COVID.
Perumal R, Shunmugam L, Naidoo K, Wilkins D, Garzino-Demo A, Brechot C, Vahlne A, Nikolich J. iScience. 2023 Jun 16;26(6):106935. doi: 10.1016/j.isci.2023.106935. Epub 2023 May 18. PMID: 37265584

Therapeutic Benefits of Melatonin Against COVID-19.
Mubashshir M, Ahmad N, Negi T, Rawal R, Singhvi N, Khatoon H, Laxmi V, Dubey O, Sharma RB, Negi G, Ovais M. Neuroimmunomodulation. 2023 Jun 19. doi: 10.1159/000531550. Online ahead of print. PMID: 37336193

Long COVID and possible preventive options.
Sebők S, Gyires K. Inflammopharmacology. 2023 Jun 21. doi: 10.1007/s10787-023-01204-1. Online ahead of print. PMID: 37344737

Public perception of COVID-19 vaccines through analysis of Twitter content and users.
Saleh SN, McDonald SA, Basit MA, Kumar S, Arasaratnam RJ, Perl TM, Lehmann CU, Medford RJ. Vaccine. 2023 Jun 23:S0264-410X(23)00743-0. doi: 10.1016/j.vaccine.2023.06.058. Online ahead of print. PMID: 37385887

Influenza and pertussis vaccine coverage in pregnancy in Australia, 2016-2021.
McRae JE, McHugh L, King C, Beard FH, Blyth CC, Danchin MH, Giles ML, Mohammed H, Wood N, Macartney K. Med J Aust. 2023 Jun 19;218(11):528-541. doi: 10.5694/mja2.51989. Epub 2023 May 29. PMID: 37248802

Initial behaviors and attitudes towards the COVID-19 vaccine in sarcoidosis patients: results of a self-reporting questionnaire.
Vagts C, Sweis JJG, Sweis NWG, Ascoli C, Rottoli P, Martone FM, Wells AU, Judson MA, Sweiss NJ, Lower EE, Baughman RP. Sarcoidosis Vasc Diffuse Lung Dis. 2023 Jun 29;40(2):e2023012. doi: 10.36141/svdld.v40i2.14388. PMID: 37382069

Effectiveness of Up-to-Date COVID-19 Vaccination in Preventing SARS-CoV-2 Infection Among Nursing Home Residents - United States, November 20, 2022-January 8, 2023.
Wong E, Barbre K, Wiegand RE, Reses HE, Dubendris H, Wallace M, Dollard P, Edwards J, Soe M, Meng L, Benin A, Bell JM. MMWR Morb Mortal Wkly Rep. 2023 Jun 23;72(25):690-693. doi: 10.15585/mmwr.mm7225a4. PMID: 37347711

COVID-19 vaccination and menstrual cycle characteristics: A prospective cohort study.
Wesselink AK, Lovett SM, Weinberg J, Geller RJ, Wang TR, Regan AK, Willis MD, Perkins RB, Yland JJ, Koenig MR, Rothman KJ, Hatch EE, Wise LA. Vaccine. 2023 Jun 29;41(29):4327-4334. doi: 10.1016/j.vaccine.2023.06.012. Epub 2023 Jun 5. PMID: 37301706

Randomized trial to evaluate the safety, tolerability, and immunogenicity of a booster (third dose) of BNT162b2 COVID-19 vaccine coadministered with 20-valent pneumococcal conjugate vaccine in adults ≥65 years old.
Fitz-Patrick D, Young M, Yacisin K, McElwee K, Belanger T, Belanger K, Peng Y, Lee DY, Gruber WC, Scott DA, Watson W. Vaccine. 2023 Jun 23;41(28):4190-4198. doi: 10.1016/j.vaccine.2023.05.002. Epub 2023 May 8. PMID: 37244809

COVID-19 vaccine acceptance and its determinants among residents of Ambo Town, West Shewa, Oromia Region, Ethiopia: cross-sectional survey.
Beressa TB, Tafa M, Geresu GD, Bacha AJ, Gadisa DA. Ther Adv Vaccines Immunother. 2023 Jun 24;11:25151355231178150. doi: 10.1177/25151355231178150. eCollection 2023. PMID: 37377465

Safety of monovalent and bivalent BNT162b2 mRNA COVID-19 vaccine boosters in at-risk populations in Israel: a large-scale, retrospective, self-controlled case series study.
Yamin D, Yechezkel M, Arbel R, Beckenstein T, Sergienko R, Duskin-Bitan H, Yaron S, Peretz A, Netzer D, Shmueli E. Lancet Infect Dis. 2023 Jun 20:S1473-3099(23)00207-4. doi: 10.1016/S1473-3099(23)00207-4. Online ahead of print. PMID: 37352878

Utilizing nanozymes for combating COVID-19: advancements in diagnostics, treatments, and preventative measures.
Wang J, Xie Q, Song H, Chen X, Zhang X, Zhao X, Hao Y, Zhang Y, Li H, Li N, Fan K, Wang X. J Nanobiotechnology. 2023 Jun 21;21(1):200. doi: 10.1186/s12951-023-01945-9. PMID: 37344839

COVID-19 vaccine uptake, confidence and hesitancy in rural KwaZulu-Natal, South Africa between April 2021 and April 2022: A continuous cross-sectional surveillance study.
Piltch-Loeb R, Mazibuko L, Stanton E, Mngomezulu T, Gareta D, Nxumalo S, Kraemer JD, Herbst K, Siedner MJ, Harling G. PLOS Glob Public Health. 2023 Jun 27;3(6):e0002033. doi: 10.1371/journal.pgph.0002033. eCollection 2023. PMID: 37368864

Neurological Disorders following COVID-19 Vaccination.
Yang Y, Huang L. Vaccines (Basel). 2023 Jun 19;11(6):1114. doi: 10.3390/vaccines11061114. PMID: 37376503

Assessment of COVID-19 Vaccine Acceptance and Its Associated Factors during the Crisis: A Community-Based Cross-Sectional Study in Benin.
Padonou SGR, Kakaï Glèlè C, Accrombessi M, Adegbite BR, Dangbenon E, Bah H, Akogbeto E, Bah Chabi AI, Kaucley L, Sourakatou S, Dossou A, Batonon A, Bissouma-Ledjou T, Hounkpatin B. Vaccines (Basel). 2023 Jun 16;11(6):1104. doi: 10.3390/vaccines11061104. PMID: 37376493

Reactogenicity and safety of COVID-19 primary immunisation and booster vaccination regimens: a comparative observational cohort study.
Warkentin L, Werner F, Zeschick N, Kühlein T, Steininger P, Überla K, Kaiser I, Sebastião M, Hueber S. BMC Med. 2023 Jun 20;21(1):218. doi: 10.1186/s12916-023-02924-5. PMID: 37340463

Alpha-1-antitrypsin antagonizes COVID-19: a review of the epidemiology, molecular mechanisms, and clinical evidence.
Bai X, Schountz T, Buckle AM, Talbert JL, Sandhaus RA, Chan ED. Biochem Soc Trans. 2023 Jun 28;51(3):1361-1375. doi: 10.1042/BST20230078. PMID: 37294003

Myositis developing after Covid-19 mRNA vaccine: Case Report.
Tosunoğlu B, Güneş HN, Çokal BG, Yoldaş TK. Acta Neurol Taiwan. 2023 Jun 30;32(2):79-81. PMID: 37198512

Uptake rates and attitudes to influenza and COVID-19 vaccination in pregnancy - a prospective cohort study.
Kelly SM, Bracken O, Bholah T, Crosby DA. Ir J Med Sci. 2023 Jun 20. doi: 10.1007/s11845-023-03428-0. Online ahead of print. PMID: 37340225

The anti-COVID-19 vaccine unveils latent systemic sclerosis.
Pelà G, Visioli F, Aiello M, Solinas E, Ferrari C, Chetta A. Scand J Rheumatol. 2023 Jun 20:1-3. doi: 10.1080/03009742.2023.2211384. Online ahead of print. PMID: 37339397

Vaccine Trust Gauge: Mixed methods research to measure and understand vaccine trust.
Masoud D, Pierz A, Rauh L, Cruz AK, Palmedo C, Ratzan S. Vaccine. 2023 Jun 17:S0264-410X(23)00690-4. doi: 10.1016/j.vaccine.2023.06.025. Online ahead of print. PMID: 37336659

Building global vaccine manufacturing capacity: Spotlight on Africa.
Rubin Thompson LJ, Grubo M, Veller M, Badenhorst RH, Nott J, Debruyne L, Makadzange T, Nicolaou S, Stanberry L, Sall A, James WG. Vaccine. 2023 Jun 19;41(27):4050-4056. doi: 10.1016/j.vaccine.2023.05.009. Epub 2023 May 11. PMID: 37173266

How to reduce vaccination hesitancy? The relevance of evidence and its communicator.
Eger J, Kaplan LC, Sternberg H. Vaccine. 2023 Jun 19;41(27):3964-3975. doi: 10.1016/j.vaccine.2023.03.026. Epub 2023 May 22. PMID: 37221120

Vaccine coverage and effectiveness against laboratory-confirmed symptomatic and severe Covid-19 in indigenous people in Brazil: a cohort study.
Pescarini JM, Cardoso AM, Santos RV, Scaff PF, Paixao ES, Ranzani OT, Cerqueira-Silva T, Boaventura VS, Bertoldo-Junior J, de Oliveira VA, Werneck GL, Barreto ML, Barral-Netto M. BMC Public Health. 2023 Jun 29;23(1):1267. doi: 10.1186/s12889-023-16196-4. PMID: 37386490

Pivoting to protein: the immunogenicity and safety of protein-based NVX-CoV2373 as a heterologous booster for inactivated and viral vector COVID-19 vaccines.
Marchese AM, Kalkeri R, Vadivale M, Suntronwong N, Toback S, Poovorawan Y. Expert Rev Vaccines. 2023 Jun 29. doi: 10.1080/14760584.2023.2232020. Online ahead of print. PMID: 37386785

Guillain-Barré Syndrome Following the BNT162b2 mRNA COVID-19 Vaccine.
Algahtani HA, Shirah BH, Albeladi YK, Albeladi RK. Acta Neurol Taiwan. 2023 Jun 30;32(2):82-85. PMID: 37198513

Using the Alluvial diagram to display variable characteristics for COVID-19 patients and research achievements on the topic of COVID-19, epidemiology, pathogenesis, and vaccine (CEPV): Bibliometric analysis.
Yen PT, Chien TW, Chou W, Tsai KT. Medicine (Baltimore). 2023 Jun 23;102(25):e33873. doi: 10.1097/MD.0000000000033873. PMID: 37352056

Illicit COVID-19 products online: A mixed-method approach for identifying and preventing online health risks.
Catalani V, Townshend HD, Prilutskaya M, Chilcott RP, Metastasio A, Banayoti H, McSweeney T, Corazza O. PLoS One. 2023 Jun 16;18(6):e0287231. doi: 10.1371/journal.pone.0287231. eCollection 2023. PMID: 37327233

COVID-19 Vaccine Hesitancy among the General Population: A Cross-Sectional Study.
Abdalla SM, Mohamed EY, Elsabagh HM, Ahmad MS, Shaik RA, Mehta V, Mathur A, Ghatge SB. Vaccines (Basel). 2023 Jun 20;11(6):1125. doi: 10.3390/vaccines11061125. PMID: 37376514

Partisan self-identification predicts attitudes of South Dakota nurses toward COVID-19 vaccine mandate for healthcare workers.
Viskupič F, Wiltse DL. Health Policy Technol. 2023 Sep;12(3):100777. doi: 10.1016/j.hlpt.2023.100777. Epub 2023 Jun 25. PMID: 37389329

Defining drivers of under-immunisation and vaccine hesitancy in refugee and migrant populations to support strategies to strengthen uptake of COVID-19 vaccines: a rapid review.

Deal A, Crawshaw AF, Carter J, Knights F, Iwami M, Darwish M, Hossain R, Immordino P, Kaojaroen K, Severoni S, Hargreaves S. J Travel Med. 2023 Jun 19:taad084. doi: 10.1093/jtm/taad084. Online ahead of print. PMID: 37335192

Effects of COVID-19 vaccination and previous SARS-CoV-2 infection on omicron infection and severe outcomes in children under 12 years of age in the USA: an observational cohort study.
Lin DY, Xu Y, Gu Y, Zeng D, Wheeler B, Young H, Moore Z, Sunny SK. Lancet Infect Dis. 2023 Jun 16:S1473-3099(23)00272-4. doi: 10.1016/S1473-3099(23)00272-4. Online ahead of print. PMID: 37336222

Social cognitive predictors of vaccination status, uptake and mitigation behaviors in the Canadian COVID-19 Experiences survey.
Hall PA, Meng G, Boudreau C, Hudson A, Quah ACK, Agar T, Fong GT. Vaccine. 2023 Jun 19;41(27):4031-4041. doi: 10.1016/j.vaccine.2022.12.010. Epub 2022 Dec 12. PMID: 36528446

GP phone calls to improve COVID-19 vaccine uptake among patients at increased risk of severe COVID-19: a randomised trial.
Tuv M, Elgersma IH, Furuseth E, Holst C, Helleve A, Fretheim A. BJGP Open. 2023 Jun 27;7(2):BJGPO.2022.0175. doi: 10.3399/BJGPO.2022.0175. Print 2023 Jun. PMID: 36754551

COVID-19, Coronavirus Vaccines, and Possible Association with Lipschütz Vulvar Ulcer: A Systematic Review.
Vismara SA, Ridolfi A, Faré PB, Bianchetti MG, Lava SAG, Renzi S, Piccoli BTB, Milani GP, Kottanattu L. Clin Rev Allergy Immunol. 2023 Jun 26. doi: 10.1007/s12016-023-08961-5. Online ahead of print. PMID: 37358748

Comparison of mRNA vaccine effectiveness against COVID-19-associated hospitalization by vaccination source: Immunization information systems, electronic medical records, and self-report-IVY Network, February 1-August 31, 2022.
Surie D, Bonnell LN, DeCuir J, Gaglani M, McNeal T, Ghamande S, Steingrub JS, Shapiro NI, Busse LW, Prekker ME, Peltan ID, Brown SM, Hager DN, Ali H, Gong MN, Mohamed A, Khan A, Wilson JG, Qadir N, Chang SY, Ginde AA, Huynh D, Mohr NM, Mallow C, Martin ET, Lauring AS, Johnson NJ, Casey JD, Gibbs KW, Kwon JH, Baughman A, Chappell JD, Hart KW, Grijalva CG, Rhoads JP, Swan SA, Keipp Talbot H, Womack KN, Zhu Y, Tenforde MW, Adams K, Self WH, McMorrow ML. Vaccine. 2023 Jun 29;41(29):4249-4256. doi: 10.1016/j.vaccine.2023.05.028. Epub 2023 May 15. PMID: 37301704

The backfiring effects of monetary and gift incentives on Covid-19 vaccination intentions.
Zhang X, Lane T. China Econ Rev. 2023 Aug;80:102009. doi: 10.1016/j.chieco.2023.102009. Epub 2023 Jun 16. PMID: 37351337

Predictors and motives for mask-wearing behavior and vaccination intention.
Binter J, Pešout O, Pieniak M, Martínez-Molina J, Noon EJ, Stefanczyk MM, Eder SJ. Sci Rep. 2023 Jun 25;13(1):10293. doi: 10.1038/s41598-023-37072-6. PMID: 37357247

Spontaneously reported adverse events following COVID-19 basic and booster immunizations in the Netherlands.
van der Boor SC, Schmitz-de Vries ETJ, Smits D, Scholl JHG, Rolfes L, van Hunsel F. Vaccine. 2023 Jun 29;41(29):4319-4326. doi: 10.1016/j.vaccine.2023.05.053. Epub 2023 May 24. PMID: 37286408

Potential impacts of SARS-CoV-2 on parathyroid: current advances and trends.
Murugan AK, Alzahrani AS. Endocrine. 2023 Jun 16. doi: 10.1007/s12020-023-03415-6. Online ahead of print. PMID: 37328666

Arrhythmias after COVID-19 Vaccination: Have We Left All Stones Unturned?
Cocco N, Leibundgut G, Pelliccia F, Cammalleri V, Nusca A, Mangiacapra F, Cocco G, Fanale V, Ussia GP, Grigioni F. Int J Mol Sci. 2023 Jun 20;24(12):10405. doi: 10.3390/ijms241210405. PMID: 37373551

Real-World Safety of COVID-19 mRNA Vaccines: A Systematic Review and Meta-Analysis.
Xu W, Ren W, Wu T, Wang Q, Luo M, Yi Y, Li J. Vaccines (Basel). 2023 Jun 19;11(6):1118. doi: 10.3390/vaccines11061118. PMID: 37376508

No immunological interference or safety concerns when adjuvanted recombinant zoster vaccine is coadministered with a COVID-19 mRNA-1273 booster vaccine in adults aged 50 years and older: A randomized trial.
Naficy A, Kuxhausen A, Pirrotta P, Leav B, Miller J, Anteyi K, Danier J, Breuer T, Mwakingwe-Omari A. Clin Infect Dis. 2023 Jun 19:ciad361. doi: 10.1093/cid/ciad361. Online ahead of print. PMID: 37335963

COVID-19 Vaccines #ForYou: Analyzing COVID-19 Vaccine Videos on TikTok During the Early Phase of the Vaccine Rollout in the U.S.
Yang B, Li Y, Terán L, Choi E, Choi Y. Health Commun. 2023 Jun 22:1-12. doi: 10.1080/10410236.2023.2227431. Online ahead of print. PMID: 37345468

Predictors of older adults' attitudes toward various COVID-19 vaccine mandates.
Viskupič F, Wiltse DL. J Aging Soc Policy. 2023 Jun 19:1-14. doi: 10.1080/08959420.2023.2226289. Online ahead of print. PMID: 37337477

Risk of myocarditis and pericarditis in mRNA COVID-19-vaccinated and unvaccinated populations: a systematic review and meta-analysis.
Alami A, Krewski D, Farhat N, Mattison D, Wilson K, Gravel CA, Farrell PJ, Crispo JAG, Haddad N, Perez-Lloret S, Villeneuve PJ. BMJ Open. 2023 Jun 20;13(6):e065687. doi: 10.1136/bmjopen-2022-065687. PMID: 37339840

National Vaccine Coverage Survey 2020: methods and operational aspects.
Barata RB, França AP, Guibu IA, Vasconcellos MTL, Moraes JC; Grupo ICV 2020. Rev Bras Epidemiol. 2023 Jun 23;26:e230031. doi: 10.1590/1980-549720230031. eCollection 2023. PMID: 37377252

Immune response after two doses of the BNT162b2 COVID-19 vaccine and risk of SARS-CoV-2 breakthrough infection in Tyrol, Austria: an open-label, observational phase 4 trial.
Seekircher L, Bánki Z, Kimpel J, Rössler A, Schäfer H, Falkensammer B, Bante D, Forer L, Schönherr S; Shieldvacc-2 Study Group; Harthaller T, Sacher M, Ower C, Tschiderer L, Ulmer H, Krammer F, von Laer D, Borena W, Willeit P. Lancet Microbe. 2023 Jun 21:S2666-5247(23)00107-6. doi: 10.1016/S2666-5247(23)00107-6. Online ahead of print. PMID: 37354911

Characterization of stability, safety and immunogenicity of the mRNA lipid nanoparticle vaccine Iribovax® against COVID-19 in nonhuman primates.

Zamani P, Mashreghi M, Bazaz MR, Zargari S, Alizadeh F, Dorrigiv M, Abdoli A, Aminianfar H, Hatamipour M, Zarqi J, Behboodifar S, Samsami Y, Sokhangouy SK, Sefidbakht Y, Uskoković V, Rezayat SM, Jaafari MR, Mozaffari-Jovin S. J Control Release. 2023 Jun 22:S0168-3659(23)00398-X. doi: 10.1016/j.jconrel.2023.06.025. Online ahead of print. PMID: 37355212

Death Anxiety Among Pakistani HCWs: The Role of COVID-19 Vaccine Acceptance and Positive Religious Coping Strategy.
Sarfraz M, Mushtaque I, Mamun MA, Raza M. Omega (Westport). 2023 Jun 28:302228231186360. doi: 10.1177/00302228231186360. Online ahead of print. PMID: 37379515

Natural heteroclitic-like peptides are generated by SARS-CoV-2 mutations.
Tiezzi C, Vecchi A, Rossi M, Cavazzini D, Bolchi A, Laccabue D, Doselli S, Penna A, Sacchelli L, Brillo F, Meschi T, Ticinesi A, Nouvenne A, Donofrio G, Zanelli P, Benecchi M, Giuliodori S, Fisicaro P, Montali I, Ceccatelli Berti C, Reverberi V, Montali A, Urbani S, Pedrazzi G, Missale G, Telenti A, Corti D, Ottonello S, Ferrari C, Boni C. iScience. 2023 Jun 16;26(6):106940. doi: 10.1016/j.isci.2023.106940. Epub 2023 May 21. PMID: 37275517

The relationship between the clinical course of SARS-CoV-2 infections and ACE2 and TMPRSS2 expression and polymorphisms.
Tug E, Fidan I, Bozdayi G, Yildirim F, Tunccan OG, Lale Z, Akdogan D. Adv Clin Exp Med. 2023 Jun 16. doi: 10.17219/acem/163409. Online ahead of print. PMID: 37326579

A qualitative study on COVID-19 pandemic impacts on parental attitudes and intentions for routine adolescent vaccinations: The role of trust.
Bolsewicz KT, Steffens MS, King C, Abdi I, Bullivant B, Beard F. Vaccine. 2023 Jun 23;41(28):4138-4143. doi: 10.1016/j.vaccine.2023.05.037. Epub 2023 May 22. PMID: 37246066

Attitudes of Islamic Clerics to Receiving COVID-19 Vaccine in Iraqi Kurdistan: A Focus Group Study.
Abdulah DM, Ahmed HM. Disaster Med Public Health Prep. 2023 Jun 19;17:e415. doi: 10.1017/dmp.2023.83. PMID: 37332164

Insights into SARS-CoV-2-associated subacute thyroiditis: from infection to vaccine.
Ziaka M, Exadaktylos A. Virol J. 2023 Jun 21;20(1):132. doi: 10.1186/s12985-023-02103-1. PMID: 37344878

COVID-19 Virus and Vaccination Attitudes among Healthcare Workers in Michigan: A Cross-Sectional Study.
Takagi MA, Hess S, Gawronski K, Haddad N, Noveloso B, Zyzanski S, Ragina N. Vaccines (Basel). 2023 Jun 16;11(6):1105. doi: 10.3390/vaccines11061105. PMID: 37376494

PEGylated Lipid Nanoparticle Formulations: Immunological Safety and Efficiency Perspective.
Tenchov R, Sasso JM, Zhou QA. Bioconjug Chem. 2023 Jun 21;34(6):941-960. doi: 10.1021/acs.bioconjchem.3c00174. Epub 2023 May 10. PMID: 37162501

Cognitive and other neuropsychiatric symptoms in COVID-19: analysis of person-generated longitudinal health data from a community-based registry.
Largent J, Xie Y, Knuth KB, Toovey S, Reynolds MW, Brinkley E, Mack CD, Dreyer NA. BMJ Open. 2023 Jun 19;13(6):e069118. doi: 10.1136/bmjopen-2022-069118. PMID: 37336535

Humoral and cellular immune responses eleven months after the third dose of BNT162b2 an mRNA-based COVID-19 vaccine in people with HIV - a prospective observational cohort study.
Heftdal LD, Pérez-Alós L, Hasselbalch RB, Hansen CB, Hamm SR, Møller DL, Pries-Heje M, Fogh K, Gerstoft J, Grønbæk K, Ostrowski SR, Frikke-Schmidt R, Sørensen E, Hilsted L, Bundgaard H, Garred P, Iversen K, Sabin C, Nielsen SD. EBioMedicine. 2023 Jun 16;93:104661. doi: 10.1016/j.ebiom.2023.104661. Online ahead of print. PMID: 37331161

Licenced doses of approved COVID-19 vaccines may not be optimal: A review of the early-phase, dose-finding trials.
Dunn DT, Gilson R, McCormack S, McCoy LE. Vaccine. 2023 Jun 16:S0264-410X(23)00712-0. doi: 10.1016/j.vaccine.2023.06.037. Online ahead of print. PMID: 37355453

Behaviors and Advocacy Related to COVID-19 among Cancer Patients: The Health Belief Model and Opportunities for Messaging and Education.
Ledford SG, Moss JL, Alles S, Wang M, Kessler FC, Marks B, Soliman AS, Joshi MD, Lengerich EJ. J Cancer Educ. 2023 Jun 20. doi: 10.1007/s13187-023-02323-7. Online ahead of print. PMID: 37336800

Estimating global changes in routine childhood vaccination coverage during the COVID-19 pandemic, 2020-2021.
Ghaznavi C, Eguchi A, Suu Lwin K, Yoneoka D, Tanoue Y, Kumar Rauniyar S, Horiuchi S, Hashizume M, Nomura S. Vaccine. 2023 Jun 23;41(28):4151-4157. doi: 10.1016/j.vaccine.2023.05.034. Epub 2023 May 22. PMID: 37246068

Bibliometric and visual analysis of vaccination hesitancy research from 2013 to 2022.
Chen C, Yang Q, Tian H, Wu J, Chen L, Ji Z, Zheng D, Chen Y, Li Z, Lu H. Hum Vaccin Immunother. 2023 Jun 30:2226584. doi: 10.1080/21645515.2023.2226584. Online ahead of print. PMID: 37387233

Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373.
Alves K, Plested JS, Galbiati S, Chau G, Cloney-Clark S, Zhu M, Kalkeri R, Patel N, Smith K, Marcheschi A, Pfeiffer S, McFall H, Smith G, Glenn GM, Dubovsky F, Mallory RM; Novavax 2019nCoV-101 Study Group. Vaccine. 2023 Jun 29;41(29):4280-4286. doi: 10.1016/j.vaccine.2023.05.051. Epub 2023 Jun 2. PMID: 37271706

Optimality of Maximal-Effort Vaccination.
Penn MJ, Donnelly CA. Bull Math Biol. 2023 Jun 23;85(8):73. doi: 10.1007/s11538-023-01179-8. PMID: 37351716

Expanding global vaccine manufacturing capacity: Strategic prioritization in small countries.
Mukherjee S, Kalra K, Phelan AL. PLOS Glob Public Health. 2023 Jun 29;3(6):e0002098. doi: 10.1371/journal.pgph.0002098. eCollection 2023. PMID: 37384623

T cell responses to SARS-CoV-2 vaccination differ by disease-modifying therapy for multiple sclerosis.
Wolf AS, Ravussin A, König M, Øverås MH, Solum G, Kjønstad IF, Chopra A, Holmøy T, Harbo HF, Syversen SW, Jørgensen KK, Høgestøl EA, Vaage JT, Celius EG, Lund-Johansen F, Munthe LA, Nygaard GO, Mjaaland S. JCI Insight. 2023 Jun 22;8(12):e165111. doi: 10.1172/jci.insight.165111. PMID: 37159281

COVID-19 Vaccine Hesitancy among English-Speaking Pregnant Women Living in Rural Western United States.
Cox E, Sanchez M, Baxter C, Crary I, Every E, Munson J, Stapley S, Stonehill A, Taylor K, Widmann W, Karasz H, Waldorf KMA. Vaccines (Basel). 2023 Jun 16;11(6):1108. doi: 10.3390/vaccines11061108. PMID: 37376496

A Comparative Case Study Analysis: Applying the HIPE Framework to Combat Harmful Health Information and Drive COVID-19 Vaccine Adoption in Underserved Communities.
Desens L, Walling B, Fiedor A, Howard V, Lopez Diaz Z, Kim K, Scannell D. Vaccines (Basel). 2023 Jun 16;11(6):1107. doi: 10.3390/vaccines11061107. PMID: 37376497

Effectiveness of the booster dose of COVID-19 vaccine in the Basque Country during the sixth wave: A nationwide cohort study.
Arrospide A, Sagardui MG, Larizgoitia I, Iturralde A, Moreda A, Mar J. Vaccine. 2023 Jun 29;41(29):4274-4279. doi: 10.1016/j.vaccine.2023.05.061. Epub 2023 May 29. PMID: 37271704

Nucleic acid biomarkers of immune response and cell and tissue damage in children with COVID-19 and MIS-C.
Loy CJ, Sotomayor-Gonzalez A, Servellita V, Nguyen J, Lenz J, Bhattacharya S, Williams ME, Cheng AP, Bliss A, Saldhi P, Brazer N, Streithorst J, Suslovic W, Hsieh CJ, Bahar B, Wood N, Foresythe A, Gliwa A, Bhakta K, Perez MA, Hussaini L, Anderson EJ, Chahroudi A, Delaney M, Butte AJ, DeBiasi RL, Rostad CA, De Vlaminck I, Chiu CY. Cell Rep Med. 2023 Jun 20;4(6):101034. doi: 10.1016/j.xcrm.2023.101034. Epub 2023 Apr 21. PMID: 37279751

How can COVID-19 vaccines benefit people? A study based on the theory of the commons.
Su Y, Li Y, Zhang S, Chen X. Hum Vaccin Immunother. 2023 Jun 20:2225991. doi: 10.1080/21645515.2023.2225991. Online ahead of print. PMID: 37340788

Incidence of myopericarditis after mRNA COVID-19 vaccination: A meta-analysis with focus on adolescents aged 12-17 years.
Guo BQ, Li HB, Yang LQ. Vaccine. 2023 Jun 23;41(28):4067-4080. doi: 10.1016/j.vaccine.2023.05.049. Epub 2023 May 22. PMID: 37246067

COVID-19 after rituximab therapy in cSLE patients.
Nelson MC, Manos CK, Flanagan E, Prahalad S. Ther Adv Vaccines Immunother. 2023 Jun 21;11:25151355231181242. doi: 10.1177/25151355231181242. eCollection 2023. PMID: 37362155

How to model the impact of vaccines for policymaking when the characteristics are uncertain: A case study in Thailand prior to the vaccine rollout during the COVID-19 pandemic.
Luangasanatip N, Painter C, Pan-Ngum W, Saralamba S, Wichaita T, White L, Aguas R, Clapham H, Wang Y, Isaranuwatchai W, Teerawattananon Y. Vaccine. 2023 Jun 20:S0264-410X(23)00740-5. doi: 10.1016/j.vaccine.2023.06.055. Online ahead of print. PMID: 37365059

Evaluation of association of anti-PEG antibodies with anaphylaxis after mRNA COVID-19 vaccination.
Zhou ZH, Cortese MM, Fang JL, Wood R, Hummell DS, Risma KA, Norton AE, KuKuruga M, Kirshner S, Rabin RL, Agarabi C, Staat MA, Halasa N, Ware RE, Stahl A, McMahon M, Browning P, Maniatis P, Bolcen S, Edwards KM, Su JR, Dharmarajan S, Forshee R, Broder KR, Anderson S, Kozlowski S.

Vaccine. 2023 Jun 23;41(28):4183-4189. doi: 10.1016/j.vaccine.2023.05.029. Epub 2023 May 16. PMID: 37244808

Prognostic improvement and treatment of COVID-19 in patients with rheumatic diseases until December 2022: Analysis of the JCR COVID-19 registry in Japan.
Kashiwado Y, Kimoto Y, Oku K, Yamamoto M, Ohshima S, Ito S, Horiuchi T, Takeuchi T. Mod Rheumatol. 2023 Jun 20:road057. doi: 10.1093/mr/road057. Online ahead of print. PMID: 37338284

GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial.
Capone S, Fusco FM, Milleri S, Borrè S, Carbonara S, Lo Caputo S, Leone S, Gori G, Maggi P, Cascio A, Lichtner M, Cauda R, Dal Zoppo S, Cossu MV, Gori A, Roda S, Confalonieri P, Bonora S, Missale G, Codeluppi M, Mezzaroma I, Capici S, Pontali E, Libanore M, Diani A, Lanini S, Battella S, Contino AM, Piano Mortari E, Genova F, Parente G, Dragonetti R, Colloca S, Visani L, Iannacone C, Carsetti R, Folgori A, Camerini R; COVITAR study group. Cell Rep Med. 2023 Jun 20;4(6):101084. doi: 10.1016/j.xcrm.2023.101084. Epub 2023 May 29. PMID: 37315558

Humoral and cell-mediated immune responses to BNT162b2 vaccine against SARS-CoV-2 in people with cystic fibrosis.
Alicandro G, Orena BS, Rosazza C, Cariani L, Russo M, Zatelli M, Badolato R, Gramegna A, Blasi F, Daccò V. Vaccine. 2023 Jun 23;41(28):4114-4120. doi: 10.1016/j.vaccine.2023.05.041. Epub 2023 May 22. PMID: 37263872

Henoch-Schönlein purpura in a 6-year-old boy after initial COVID-19 vaccination.
de Souza Campos Fernandes RC, Nunes DV, de Almeida NF, da Cruz Assad Monteiro N, Pimenta LAM, Medina-Acosta E. Vaccine X. 2023 Aug;14:100333. doi: 10.1016/j.jvacx.2023.100333. Epub 2023 Jun 20. PMID: 37362023

[Temporal relationships between a state of emergency declaration or request and trends in the incidence of unlinked COVID-19 cases in Osaka from October 2020 to May 2021].
Takahashi Y, Morisada K, Watanabe M, Tanaka H. Nihon Koshu Eisei Zasshi. 2023 Jun 24;70(6):390-399. doi: 10.11236/jph.22-041. Epub 2023 Mar 10. PMID: 36908155

Biomaterial-based delivery platforms for transdermal immunotherapy.
Dahri M, Beheshtizadeh N, Seyedpour N, Nakhostin-Ansari A, Aghajani F, Seyedpour S, Masjedi M, Farjadian F, Maleki R, Adibkia K. Biomed Pharmacother. 2023 Jun 27;165:115048. doi: 10.1016/j.biopha.2023.115048. Online ahead of print. PMID: 37385212

COVID-19 Vaccine Effectiveness Among Patients With Maintenance Dialysis; Observations From Population Level Cohort Studies in 2 Large Canadian Provinces.
Atiquzzaman M, Zheng Y, Er L, Djurdjev O, Singer J, Krajden M, Balamchi S, Thomas D, Hladunewich M, Oliver MJ, Levin A. Can J Kidney Health Dis. 2023 Jun 21;10:20543581231181032. doi: 10.1177/20543581231181032. eCollection 2023. PMID: 37359985

Data Mining Pipeline for COVID-19 Vaccine Safety Analysis Using a Large Electronic Health Record.
Huang Y, Li X, Dongarwar D, Wu H, Zhang GQ. AMIA Jt Summits Transl Sci Proc. 2023 Jun 16;2023:271-280. eCollection 2023. PMID: 37350900

Real-world effectiveness of nirmatrelvir/ritonavir against COVID-19 hospitalisations and severe COVID-19 in community-dwelling elderly Singaporeans during Omicron BA.2, BA.4/5 and XBB transmission.
Wee LE, Tay AT, Chiew C, Young BE, Wong B, Lim R, Lee CL, Tan J, Vasoo S, Lye DC, Tan KB. Clin Microbiol Infect. 2023 Jun 16:S1198-743X(23)00294-X. doi: 10.1016/j.cmi.2023.06.016. Online ahead of print. PMID: 37331509

Vaccination in sickle cell disease: Immunocompromised or immunocompetent?
Han J, Saraf SL, Gordeuk VR. Br J Haematol. 2023 Jun 22. doi: 10.1111/bjh.18942. Online ahead of print. PMID: 37350061

Mixed messages and COVID-19 prevention: Why information isn't always enough to protect meat processing workers.
Sivén JM, Coburn J, Call TP, Mahoney D, Flores RR, Kaur H, Flynn MA, Menéndez CC. AJPM Focus. 2023 Jun 21:100128. doi: 10.1016/j.focus.2023.100128. Online ahead of print. PMID: 37362400

Vaccine-carditis study: Spanish multicenter registry of inflammatory heart disease after COVID-19 vaccination.
Pastor Pueyo P, Gambó Ruberte E, Gayán Ordás J, Matute Blanco L, Pascual Figal D, Larrañaga Moreira JM, Gómez Barrado JJ, González Calle D, Almenar Bonet L, Alonso Salinas GL, Corbí Pascual MJ, Plaza Martín M, Pons Llinares J, Durante López A, Barreiro Pérez M, Candanedo Ocaña F, Bautista García J, Merchán Ortega G, Domínguez Rodríguez F, Martínez Mateo V, Campreciós Crespo M, Quintás Guzmán M, Jordán Martínez L, Aboal Viñas J, Rodríguez López J, Fernández Santos S, Revilla Martí P, Álvarez Roy L, Gómez Polo JC, García Pinilla JM, Ferré Vallverdú M, García Bueno L, Soriano Colomé T, Worner Diz F. Clin Res Cardiol. 2023 Jun 27. doi: 10.1007/s00392-023-02225-0. Online ahead of print. PMID: 37368015

Travel vaccines-priorities determined by incidence and impact.
Steffen R, Chen LH, Leggat PA. J Travel Med. 2023 Jun 21:taad085. doi: 10.1093/jtm/taad085. Online ahead of print. PMID: 37341307

Aspect-based classification of vaccine misinformation: a spatiotemporal analysis using Twitter chatter.
Ismail H, Hussein N, Elabyad R, Abdelhalim S, Elhadef M. BMC Public Health. 2023 Jun 21;23(1):1193. doi: 10.1186/s12889-023-16067-y. PMID: 37340455

Retinal vascular occlusion following SARS-CoV-2 vaccination: A VAERS database analysis.
Singh RB, Parmar UPS, Gupta R, Vega Garcia AJ, Cho W, Singh KP, Agarwal A. Ophthalmol Sci. 2023 Jun 20:100354. doi: 10.1016/j.xops.2023.100354. Online ahead of print. PMID: 37362418

Mining Greek Tweets on Long COVID Using Sentiment Analysis and Topic Modeling.
Katika A, Zoulias E, Koufi V, Malamateniou F. Stud Health Technol Inform. 2023 Jun 29;305:545-548. doi: 10.3233/SHTI230554. PMID: 37387088

Diagnosis of Multisystem Inflammatory Syndrome in Children by a Whole-Blood Transcriptional Signature.
Jackson HR, Miglietta L, Habgood-Coote D, D'Souza G, Shah P, Nichols S, Vito O, Powell O, Davidson MS, Shimizu C, Agyeman PKA, Beudeker CR, Brengel-Pesce K, Carrol ED, Carter MJ, De T, Eleftheriou I, Emonts M, Epalza C, Georgiou P, De Groot R, Fidler K, Fink C, van Keulen D, Kuijpers T, Moll H, Papatheodorou I, Paulus S, Pokorn M, Pollard AJ, Rivero-Calle I, Rojo P, Secka F, Schlapbach LJ,

Tremoulet AH, Tsolia M, Usuf E, Van Der Flier M, Von Both U, Vermont C, Yeung S, Zavadska D, Zenz W, Coin LJM, Cunnington A, Burns JC, Wright V, Martinon-Torres F, Herberg JA, Rodriguez-Manzano J, Kaforou M, Levin M. J Pediatric Infect Dis Soc. 2023 Jun 30;12(6):322-331. doi: 10.1093/jpids/piad035. PMID: 37255317

Anthracyclines inhibit SARS-CoV-2 infection.
Wang Z, Pan Q, Ma L, Zhao J, McIntosh F, Liu Z, Ding S, Lin R, Chen S, Finzi A, Liang C. Virus Res. 2023 Jun 26:199164. doi: 10.1016/j.virusres.2023.199164. Online ahead of print. PMID: 37379907

Factors that influenced utilization of antenatal and immunization services in two local government areas in The Gambia during COVID-19: An interview-based qualitative study.
Bah A, Russo G. PLoS One. 2023 Jun 29;18(6):e0276357. doi: 10.1371/journal.pone.0276357. eCollection 2023. PMID: 37384645

Acceptance of COVID-19 vaccination among parents of children with autism and other neurodevelopmental disorders in Saudi Arabia: a cross-sectional study.
Al Saad AJ, Alhassan GM, Albedaiwi MS, Alqattan FF, Alessa FA, Alabdulmohsen HW. BMC Public Health. 2023 Jun 26;23(1):1235. doi: 10.1186/s12889-023-16127-3. PMID: 37365523

Maternal and Cord Anti-SARS-CoV-2-Spike IgG following COVID-19 Vaccination versus Infection during Pregnancy: A Prospective Study, Israel October 2021-March 2022.
Abu Shqara R, Frank Wolf M, Mikhail Mustafa S, Sgayer I, Assulyn T, Abu Zraki A, Askhar Majadla N, Rechnizter H, Shehadeh M, Fleisher Sheffer V, Bordeynik-Cohen M, Yakir O, Lowenstein L, Sela E, Edelstein M, Dror AA. Am J Perinatol. 2023 Jun 19. doi: 10.1055/a-2090-5402. Online ahead of print. PMID: 37164317

A case with prolonged headache after COVID-19 vaccination and later developed Bell's palsy.
Hsiao YY, Liu LJ, Lin YL. Acta Neurol Taiwan. 2023 Jun 30;32(2):65-68. PMID: 37198509

Factors associated with receipt of mRNA-1273 vaccine at a United States national retail pharmacy during the COVID-19 pandemic.
Roberts-McCarthy E, Buck PO, Smith-Ray RL, Van de Velde N, Singh T, Mansi J, Shah A, Taitel M. Vaccine. 2023 Jun 29;41(29):4257-4266. doi: 10.1016/j.vaccine.2023.03.076. Epub 2023 May 11. PMID: 37296016

Immunogenicity, efficacy, and safety of CoronaVac and Pfizer/BioNTech mRNA vaccines in patients with psoriasis receiving systemic therapies: A prospective cohort study.
Ergun T, Hosgoren Tekin S, Apti Sengun O, Akin Cakici O, Seckin D, Adiay C, Enul H, Yilmaz S, Ay P, Haklar G, Sili U. Vaccine. 2023 Jun 29;41(29):4287-4294. doi: 10.1016/j.vaccine.2023.05.052. Epub 2023 Jun 3. PMID: 37277251

Immune response to COVID-19 vaccination in a population with a history of elevated exposure to per- and polyfluoroalkyl substances (PFAS) through drinking water.
Bailey JM, Wang L, McDonald JM, Gray JS, Petrie JG, Martin ET, Savitz DA, Karrer TA, Fisher KA, Geiger MJ, Wasilevich EA. J Expo Sci Environ Epidemiol. 2023 Jun 19. doi: 10.1038/s41370-023-00564-8. Online ahead of print. PMID: 37337047

Safety and tolerability study of sotrovimab (VIR-7831) prophylaxis against COVID-19 infection in immunocompromised individuals with impaired SARS-CoV-2 humoral immunity.
Gonzalez-Bocco IH, Beluch K, Cho A, Lahoud C, Reyes FA, Moshovitis DG, Unger-Mochrie GM, Wang W, Hammond SP, Manne-Goehler J, Koo S. Pilot Feasibility Stud. 2023 Jun 16;9(1):100. doi: 10.1186/s40814-023-01325-y. PMID: 37328890

Recent Advances in Site-Specific Lipid Nanoparticles for mRNA Delivery.
Xu X, Xia T. ACS Nanosci Au. 2023 Mar 30;3(3):192-203. doi: 10.1021/acsnanoscienceau.2c00062. eCollection 2023 Jun 21. PMID: 37360845

COVID-19 Vaccination Acceptability: A Cross-Sectional Study Among Lebanese Residents.
Domiati S, Hodeib F, El Majzoub R, Sacre H. Disaster Med Public Health Prep. 2023 Jun 30;17:e421. doi: 10.1017/dmp.2023.89. PMID: 37385751

Assessment of humoral and cellular immunity after bivalent BNT162b2 vaccination and potential association with reactogenicity.
Salvagno GL, Pighi L, Henry BM, Valentini M, Tonin B, Bragantini D, Gianfilippi G, De Nitto S, Plebani M, Lippi G. Clin Chem Lab Med. 2023 Feb 2;61(7):1343-1348. doi: 10.1515/cclm-2023-0055. Print 2023 Jun 27. PMID: 36722026

Acute macular neuroretinopathy following Moderna COVID-19 vaccination.
Protsyk O, Gallego-Pinazo R, Dolz-Marco R. J Ophthalmic Inflamm Infect. 2023 Jun 29;13(1):30. doi: 10.1186/s12348-023-00354-1. PMID: 37382778

Sexual orientation was associated with intention to be vaccinated with a smallpox vaccine against mpox: A cross-sectional preliminary survey in Japan.
Hori D, Kaneda Y, Ozaki A, Tabuchi T. Vaccine. 2023 Jun 19;41(27):3954-3959. doi: 10.1016/j.vaccine.2023.05.050. Epub 2023 May 24. PMID: 37236819

Cerebral venous sinus thrombosis due to vaccine-induced immune thrombotic thrombocytopenia in middle-income countries.
van de Munckhof A, Borhani-Haghighi A, Aaron S, Krzywicka K, van Kammen MS, Cordonnier C, Kleinig TJ, Field TS, Poli S, Lemmens R, Scutelnic A, Lindgren E, Duan J, Arslan Y, van Gorp EC, Kremer Hovinga JA, Günther A, Jood K, Tatlisumak T, Putaala J, Heldner MR, Arnold M, de Sousa DA, Wasay M, Arauz A, Conforto AB, Ferro JM, Coutinho JM; Cerebral Venous Sinus Thrombosis with Thrombocytopenia Syndrome Study Group. Int J Stroke. 2023 Jun 30:17474930231182901. doi: 10.1177/17474930231182901. Online ahead of print. PMID: 37277922

Vaccine-Induced Immune Thrombotic Thrombocytopenia following BNT162b2 mRNA COVID-19 Booster: A Case Report.
Lin TC, Fu PA, Hsu YT, Chen TY. Vaccines (Basel). 2023 Jun 19;11(6):1115. doi: 10.3390/vaccines11061115. PMID: 37376504

A case of recurrence of pyoderma gangrenosum after COVID-19 vaccine.
Bettolini L, Bighetti S, Mezzana S, Gelmetti A, Calzavara-Pinton P, Maione V. J Eur Acad Dermatol Venereol. 2023 Jun 20. doi: 10.1111/jdv.19285. Online ahead of print. PMID: 37338337

SARS-CoV-2: analysis of the effects of mutations in non-structural proteins.
Senthilazhagan K, Sakthimani S, Kallanja D, Venkataraman S. Arch Virol. 2023 Jun 21;168(7):186. doi: 10.1007/s00705-023-05818-2. PMID: 37344726

The Recent Outbreak of COVID-19 in China During the Omicron Variant Predominance: Clinical Features and Outcomes in Patients with Autoimmune Inflammatory Rheumatic Diseases.
Geng Y, Fan Y, Deng X, Wang Y, Zhao J, Ji L, Song Z, Li G, Zhang X, Sun X, Huang H, Xie W, Zhang Z. Rheumatol Ther. 2023 Jun 19. doi: 10.1007/s40744-023-00569-7. Online ahead of print. PMID: 37335431

Missed Opportunities for Adolescent Immunizations at Well-Care Visits During the COVID-19 Pandemic.
Kelly MK, Stephens-Shields AJ, Hannan C, Rand CM, Localio R, Shone LP, Steffes J, Davis K, Grundmeier RW, Humiston SG, Albertin C, McFarland G, Abney DE, Szilagyi PG, Fiks AG. J Adolesc Health. 2023 Jun 29:S1054-139X(23)00267-7. doi: 10.1016/j.jadohealth.2023.05.008. Online ahead of print. PMID: 37389529

Evaluation of non-clinical toxicity studies of COVID-19 vaccines.
Schilder NKM, Tiesjema B, Theunissen PT, Rengerink KO, van der Laan JW. Regul Toxicol Pharmacol. 2023 Jun 23:105438. doi: 10.1016/j.yrtph.2023.105438. Online ahead of print. PMID: 37356612

Clinico-epidemiological profile and outcome of infected health care workers during the three consecutive waves of COVID-19 pandemic: a longitudinal cohort study.
Mathew M, Sebastian J, Doddaiah N, Thomas A, Narayanappa S. Ther Adv Vaccines Immunother. 2023 Jun 21;11:25151355231181744. doi: 10.1177/25151355231181744. eCollection 2023. PMID: 37362156

Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A Randomised Controlled Trial.
Kelly E, Greenland M, de Whalley PCS, Aley PK, Plested EL, Singh N, Koleva S, Tonner S, Macaulay GC, Read RC, Ramsay M, Cameron JC, Turner DPJ, Heath PT, Bernatoniene J, Connor P, Cathie K, Faust SN, Banerjee I, Cantrell L, Mujadidi YF, Belhadef HT, Clutterbuck EA, Anslow R, Valliji Z, James T, Hallis B, Otter AD, Lambe T, Nguyen-Van-Tam JS, Minassian AM, Liu X, Snape MD; Com-COV3 Study Group. J Infect. 2023 Jun 16:S0163-4453(23)00330-4. doi: 10.1016/j.jinf.2023.06.007. Online ahead of print. PMID: 37331429

Autoimmune hepatitis following COVID-19 vaccination: Clinical characteristics of 35 reported cases.
Wang M, Qi J, Liu Y. Drug Discov Ther. 2023 Jun 16. doi: 10.5582/ddt.2023.01022. Online ahead of print. PMID: 37331808

Validity of Rapid Antibody Testing for COVID-19 Vaccine in Homeless People.
Hwang SM, Jung Y, Seo J, Jung Y, Park S, Seo H. Viruses. 2023 Jun 20;15(6):1400. doi: 10.3390/v15061400. PMID: 37376699

Identifying and addressing the impacts of the COVID-19 pandemic on school-based immunisation programmes in the Canadian Maritimes: a mixed methods study protocol.
Gallant AJ, Steenbeek A, Halperin SA, Parsons Leigh J, Curran JA. BMJ Open. 2023 Jun 26;13(6):e073172. doi: 10.1136/bmjopen-2023-073172. PMID: 37369397

One year safety and immunogenicity of AZD1222 (ChAdOx1 nCoV-19): Final analysis of a randomized, placebo-controlled phase 1/2 trial in Japan.
Ishikawa K, Nascimento MC, Asano M, Hirata H, Itoh Y, Kelly EJ, Matsui A, Olsson U, Shoemaker K, Green J. Vaccine. 2023 Jun 29;41(29):4199-4205. doi: 10.1016/j.vaccine.2023.05.015. Epub 2023 Jun 2. PMID: 37271703

Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial.
Brown SM, Barkauskas CE, Grund B, Sharma S, Phillips AN, Leither L, Peltan ID, Lanspa M, Gilstrap DL, Mourad A, Lane K, Beitler JR, Serra AL, Garcia I, Almasri E, Fayed M, Hubel K, Harris ES, Middleton EA, Barrios MAG, Mathews KS, Goel NN, Acquah S, Mosier J, Hypes C, Salvagio Campbell E, Khan A, Hough CL, Wilson JG, Levitt JE, Duggal A, Dugar S, Goodwin AJ, Terry C, Chen P, Torbati S, Iyer N, Sandkovsky US, Johnson NJ, Robinson BRH, Matthay MA, Aggarwal NR, Douglas IS, Casey JD, Hache-Marliere M, Georges Youssef J, Nkemdirim W, Leshnower B, Awan O, Pannu S, O'Mahony DS, Manian P, Awori Hayanga JW, Wortmann GW, Tomazini BM, Miller RF, Jensen JU, Murray DD, Bickell NA, Zatakia J, Burris S, Higgs ES, Natarajan V, Dewar RL, Schechner A, Kang N, Arenas-Pinto A, Hudson F, Ginde AA, Self WH, Rogers AJ, Oldmixon CF, Morin H, Sanchez A, Weintrob AC, Cavalcanti AB, Davis-Karim A, Engen N, Denning E, Taylor Thompson B, Gelijns AC, Kan V, Davey VJ, Lundgren JD, Babiker AG, Neaton JD, Lane HC; ACTIV-3b/Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Study Group. Lancet Respir Med. 2023 Jun 19:S2213-2600(23)00147-9. doi: 10.1016/S2213-2600(23)00147-9. Online ahead of print. PMID: 37348524

COVID-19 Adenoviral Vector Vaccination Elicits a Robust Memory B Cell Response with the Capacity to Recognize Omicron BA.2 and BA.5 Variants.
Fryer HA, Hartley GE, Edwards ESJ, Varese N, Boo I, Bornheimer SJ, Hogarth PM, Drummer HE, O'Hehir RE, van Zelm MC. J Clin Immunol. 2023 Jun 16. doi: 10.1007/s10875-023-01527-2. Online ahead of print. PMID: 37322095

The Prevalence of COVID-19 Vaccine Hesitancy Among the Black Asian Ethnic Minority in New South Wales, Australia.
Zengeni M, Briggs NN. Cureus. 2023 Jun 19;15(6):e40626. doi: 10.7759/cureus.40626. eCollection 2023 Jun. PMID: 37350977

Serological response following COVID-19 vaccines in patients living with HIV: a dose-response meta-analysis.
Zhou Q, Zeng F, Meng Y, Liu Y, Liu H, Deng G. Sci Rep. 2023 Jun 19;13(1):9893. doi: 10.1038/s41598-023-37051-x. PMID: 37336939

Interim Recommendations for Use of Bivalent mRNA COVID-19 Vaccines for Persons Aged ≥6 Months - United States, April 2023.
Moulia DL, Wallace M, Roper LE, Godfrey M, Rosenblum HG, Link-Gelles R, Britton A, Daley MF, Meyer S, Fleming-Dutra KE, Oliver SE, Twentyman E. MMWR Morb Mortal Wkly Rep. 2023 Jun 16;72(24):657-662. doi: 10.15585/mmwr.mm7224a3. PMID: 37319020

The Role of Sudanese Doctors in the United Kingdom in Mitigating COVID-19 Vaccine Hesitancy Among Their Diaspora Communities.

Hashim A, Taha Y. Glob Health Sci Pract. 2023 Jun 21;11(3):e2200447. doi: 10.9745/GHSP-D-22-00447. Print 2023 Jun 21. PMID: 37348947

Risk of congenital malformation following first trimester mRNA COVID-19 vaccine exposure in pregnancy: the COVI-PREG prospective cohort.
Favre G, Maisonneuve E, Pomar L, Daire C, Monod C, Martinez de Tejada B, Quibel T, Bernasconi MT, Sentilhes L, Blume C, Papadia A, Sturm S, Bassler D, Grawe C, Radan AP, Rossier MC, Mathis J, Brugger RC, Lepigeon K, Gerbier E, Addor MC, Winterfeld U, Baud D, Panchaud A; COVI-PREG group. Clin Microbiol Infect. 2023 Jun 19:S1198-743X(23)00293-8. doi: 10.1016/j.cmi.2023.06.015. Online ahead of print. PMID: 37343619

Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial.
Lee IT, Cosgrove CA, Moore P, Bethune C, Nally R, Bula M, Kalra PA, Clark R, Dargan PI, Boffito M, Sheridan R, Moran E, Darton TC, Burns F, Saralaya D, Duncan CJA, Lillie PJ, San Francisco Ramos A, Galiza EP, Heath PT, Girard B, Parker C, Rust D, Mehta S, de Windt E, Sutherland A, Tomassini JE, Dutko FJ, Chalkias S, Deng W, Chen X, Feng J, Tracy L, Zhou H, Miller JM, Das R; Study Investigators. Lancet Infect Dis. 2023 Jun 19:S1473-3099(23)00295-5. doi: 10.1016/S1473-3099(23)00295-5. Online ahead of print. PMID: 37348519

Epidemiological study of vaccination against SARS-CoV-2 and its impact on COVID-19 progression in a cohort of patients in gran Canaria.
de Arriba Fernández A, Bilbao JLA, Francés AE, Mora AC, Pérez ÁG, Barreiros MÁD. Vacunas. 2023 Jun 23. doi: 10.1016/j.vacun.2023.06.005. Online ahead of print. PMID: 37366493

Disparities in COVID-19 Disease Incidence by Income and Vaccination Coverage - 81 Communities, Los Angeles, California, July 2020-September 2021.
Masterson JM, Luu M, Dallas KB, Daskivich LP, Spiegel B, Daskivich TJ. MMWR Morb Mortal Wkly Rep. 2023 Jun 30;72(26):728-731. doi: 10.15585/mmwr.mm7226a5. PMID: 37384567

Global COVID-19 Policy Engagement With Scientific Research Information: Altmetric Data Study.
Park HW, Yoon HY. J Med Internet Res. 2023 Jun 29;25:e46328. doi: 10.2196/46328. PMID: 37384384

Impact of the COVID-19 vaccination mandate on the primary care workforce and differences between rural and urban settings to inform future policy decision-making.
Hatch BA, Kenzie E, Ramalingam N, Sullivan E, Barnes C, Elder N, Davis MM. PLoS One. 2023 Jun 27;18(6):e0287553. doi: 10.1371/journal.pone.0287553. eCollection 2023. PMID: 37368922

A rare presentation of rapidly progressing myopathy in an adolescent.
Pepys J, Borchert RJ, Thambirajah N, Daruwalla C, Apostolopoulos D, O'Donovan DG, Ham T, Brierley C. Mod Rheumatol Case Rep. 2023 Jun 19;7(2):410-415. doi: 10.1093/mrcr/rxac097. PMID: 36562098

Immunological responses and adverse reactions of the heterologous second booster dose of BNT162b2 after two-dose CoronaVac for COVID-19 vaccination in healthcare workers of Faculty of Medicine, Naresuan University.
Makanut S, Wangteeraprasert A, Jitpewngam W, Ngoenkam J, Pongcharoen S. Vaccine. 2023 Jun 29;41(29):4335-4340. doi: 10.1016/j.vaccine.2023.06.017. Epub 2023 Jun 5. PMID: 37301707

Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial.
Li JX, Hou LH, Gou JB, Yin ZD, Wu SP, Wang FZ, Zhang Z, Peng ZH, Zhu T, Shen HB, Chen W, Zhu FC; Six-Province COVID-19 Vaccine Study Group. Lancet Infect Dis. 2023 Jun 20:S1473-3099(23)00350-X. doi: 10.1016/S1473-3099(23)00350-X. Online ahead of print. PMID: 37352880

Risk Factors and Disease Profile Associated with the Nucleic Acid Conversion Time of COVID-19 Patients Infected with the SARS-CoV-2 Omicron Variant in Fangcang Shelter Hospitals.
Ma S, Wang H, Zhu K, Chen H, Xie J, Huang Y. Infect Drug Resist. 2023 Jun 20;16:3945-3954. doi: 10.2147/IDR.S410086. eCollection 2023. PMID: 37361936

Discovery of Peptidic Ligands against the SARS-CoV-2 Spike Protein and Their Use in the Development of a Highly Sensitive Personal Use Colorimetric COVID-19 Biosensor.
Yu X, Pan B, Zhao C, Shorty D, Solano LN, Sun G, Liu R, Lam KS. ACS Sens. 2023 Jun 23;8(6):2159-2168. doi: 10.1021/acssensors.2c02386. Epub 2023 May 30. PMID: 37253267

Rational design and combinatorial chemistry of ionizable lipids for RNA delivery.
Xu Y, Golubovic A, Xu S, Pan A, Li B. J Mater Chem B. 2023 Jun 22. doi: 10.1039/d3tb00649b. Online ahead of print. PMID: 37345430

Advances in mRNA Therapeutics for Cancer Immunotherapy: From Modification to Delivery.
Han G, Noh D, Lee H, Lee S, Kim S, Yeol Yoon H, Hyeon Lee S. Adv Drug Deliv Rev. 2023 Jun 25;199:114973. doi: 10.1016/j.addr.2023.114973. Online ahead of print. PMID: 37369262

Immunogenicity and safety of heterologous immunisation with Ad5-nCOV in healthy adults aged 60 years and older primed with an inactivated SARS-CoV-2 vaccine (CoronaVac): a phase 4, randomised, observer-blind, non-inferiority trial.
Jin PF, Guo XL, Gou JB, Hou LH, Song ZZ, Zhu T, Pan HX, Zhu JH, Shi FJ, Du P, Huang HT, Liu JX, Zheng H, Wang X, Chen Y, Wan P, Wu SP, Wang XW, Xu XY, Yan FR, Li JX, Chen W, Zhu FC. Lancet Reg Health West Pac. 2023 Jun 20:100829. doi: 10.1016/j.lanwpc.2023.100829. Online ahead of print. PMID: 37360864

Vaccine-incentivized blood donation: A survey of public perceptions in Canada.
Stoklosa K, Elfaki LA, Ding C, Sachal SS, Escuardo RJ, Tu K. Vox Sang. 2023 Jun 29. doi: 10.1111/vox.13484. Online ahead of print. PMID: 37381906

COVID-19 Vaccination Personas in Syria: Evidence from a Cross-Sectional Survey.
Nikoloski Z, Aliyev E, Bain RES, Menchini L, Hegazi S, Zalkha M, Mouawad S, Kapil N, Gillespie AM. Vaccines (Basel). 2023 Jun 16;11(6):1109. doi: 10.3390/vaccines11061109. PMID: 37376498

Integrating the person-centered approach with the study of vaccine hesitancy: Applying latent profile analysis to identify vaccine hesitancy subpopulations and assess their relations with correlates and vaccination outcomes.
Howard MC. Vaccine. 2023 Jun 23:S0264-410X(23)00742-9. doi: 10.1016/j.vaccine.2023.06.057. Online ahead of print. PMID: 37357075

Positively Charged-Amylose-Entangled Au-Nanoparticles Acting as Protein Carriers and Potential Adjuvants to SARS-CoV-2 Subunit Vaccines.
Fan B, Gu J, Deng B, Guo W, Zhang S, Li L, Li B. ACS Appl Mater Interfaces. 2023 Jun 28;15(25):29982-29997. doi: 10.1021/acsami.3c05295. Epub 2023 Jun 18. PMID: 37330942

Comment on Determinants of the Attitude to COVID-19 Vaccine.
Kleebayoon A, Wiwanitkit V. SAGE Open Nurs. 2023 Jun 20;9:23779608231173496. doi: 10.1177/23779608231173496. eCollection 2023 Jan-Dec. PMID: 37362952

Nanostructures for prevention, diagnosis, and treatment of viral respiratory infections: from influenza virus to SARS-CoV-2 variants.
Sharifi E, Yousefiasl S, Trovato M, Sartorius R, Esmaeili Y, Goodarzi H, Ghomi M, Bigham A, Moghaddam FD, Heidarifard M, Pourmotabed S, Nazarzadeh Zare E, Paiva-Santos AC, Rabiee N, Wang X, Tay FR. J Nanobiotechnology. 2023 Jun 21;21(1):199. doi: 10.1186/s12951-023-01938-8. PMID: 37344894

In silico screening of potential inhibitors from Cordyceps species against SARS-CoV-2 main protease.
Deshmukh N, Talkal R, Lakshmi B. J Biomol Struct Dyn. 2023 Jun 16:1-17. doi: 10.1080/07391102.2023.2225110. Online ahead of print. PMID: 37325819

Multi-omic longitudinal study reveals immune correlates of clinical course among hospitalized COVID-19 patients.
Diray-Arce J, Fourati S, Doni Jayavelu N, Patel R, Maguire C, Chang AC, Dandekar R, Qi J, Lee BH, van Zalm P, Schroeder A, Chen E, Konstorum A, Brito A, Gygi JP, Kho A, Chen J, Pawar S, Gonzalez-Reiche AS, Hoch A, Milliren CE, Overton JA, Westendorf K; IMPACC Network; Cairns CB, Rouphael N, Bosinger SE, Kim-Schulze S, Krammer F, Rosen L, Grubaugh ND, van Bakel H, Wilson M, Rajan J, Steen H, Eckalbar W, Cotsapas C, Langelier CR, Levy O, Altman MC, Maecker H, Montgomery RR, Haddad EK, Sekaly RP, Esserman D, Ozonoff A, Becker PM, Augustine AD, Guan L, Peters B, Kleinstein SH. Cell Rep Med. 2023 Jun 20;4(6):101079. doi: 10.1016/j.xcrm.2023.101079. Epub 2023 May 23. PMID: 37327781

Analysis of Factors Influencing the Clinical Severity of Omicron and Delta Variants.
Zhao S, Luo K, Guo Y, Fang M, Sun Q, Dai Z, Yang H, Zhan Z, Hu S, Chen T, Li X. Trop Med Infect Dis. 2023 Jun 20;8(6):330. doi: 10.3390/tropicalmed8060330. PMID: 37368748

Correlates of support for international vaccine solidarity during the COVID-19 pandemic: Cross-sectional survey evidence from Germany.
Stoeckel F, Thompson J, Szewach P, Stöckli S, Barnfield M, Phillips JB, Lyons B, Mérola V, Reifler J. PLoS One. 2023 Jun 23;18(6):e0287257. doi: 10.1371/journal.pone.0287257. eCollection 2023. PMID: 37352321

Exploring the potential benefits of mucosal COVID-19 vaccines: opportunities and challenges.
Croda J. Lancet Infect Dis. 2023 Jun 20:S1473-3099(23)00363-8. doi: 10.1016/S1473-3099(23)00363-8. Online ahead of print. PMID: 37352881

Accuracy of Self-Reported COVID-19 Vaccination Status Compared With a Public Health Vaccination Registry in Québec: Observational Diagnostic Study.
Archambault PM, Rosychuk RJ, Audet M, Bola R, Vatanpour S, Brooks SC, Daoust R, Clark G, Grant L, Vaillancourt S, Welsford M, Morrison LJ, Hohl CM; Canadian COVID-19 Emergency Department Rapid

Response Network (CCEDRRN) investigators; Network of Canadian Emergency Researchers; Canadian Critical Care Trials Group. JMIR Public Health Surveill. 2023 Jun 16;9:e44465. doi: 10.2196/44465. PMID: 37327046

An adenoviral-vectored vaccine confers seroprotection against capsular group B meningococcal disease.
Dold C, Marsay L, Wang N, Silva-Reyes L, Clutterbuck E, Paterson GK, Sharkey K, Wyllie D, Beernink PT, Hill AV, Pollard AJ, Rollier CS. Sci Transl Med. 2023 Jun 21;15(701):eade3901. doi: 10.1126/scitranslmed.ade3901. Epub 2023 Jun 21. PMID: 37343082

A SARS-CoV-2 and influenza double hit vaccine based on RBD-conjugated inactivated influenza A virus.
Wang Z, Li Z, Shi W, Zhu D, Hu S, Dinh PC, Cheng K. Sci Adv. 2023 Jun 23;9(25):eabo4100. doi: 10.1126/sciadv.abo4100. Epub 2023 Jun 23. PMID: 37352360

Response to Letter to the Editor From Zhang et al: "Effect of Inactivated and mRNA COVID-19 Vaccination on Thyroid Function Among Patients Treated for Hyperthyroidism".
Wong CH, Leung EKH, Tang LCK, Lee CH, Fong CHY, Lee ACH, Woo YC, Tan KCB, Lui DTW. J Clin Endocrinol Metab. 2023 Jun 16;108(7):e499-e500. doi: 10.1210/clinem/dgad093. PMID: 36848150

Human circulating and tissue-resident memory $CD8^+$ T cells.
Buggert M, Price DA, Mackay LK, Betts MR. Nat Immunol. 2023 Jul;24(7):1076-1086. doi: 10.1038/s41590-023-01538-6. Epub 2023 Jun 22. PMID: 37349380

Kikuchi-Fujimoto Disease in the Axilla after COVID-19 Vaccination: A Case Report.
Cho E, Baek HJ, Bae K, Jeon KN, Moon JI, Park SE, Lee HS, An HJ. Curr Med Imaging. 2023 Jun 20. doi: 10.2174/1573405620666230620115956. Online ahead of print. PMID: 37340742

Evaluation of Anti-S1 IgA Response to Different COVID-19 Vaccination Regimens.
Bureerug TC, Kanokudom S, Suntronwong N, Yorsaeng R, Assawakosri S, Thongmee T, Poovorawan Y. Vaccines (Basel). 2023 Jun 19;11(6):1117. doi: 10.3390/vaccines11061117. PMID: 37376506

Multisystem inflammatory syndrome in children: an evolving understanding of a syndrome amid the inflammatory continuum.
Areti S, Parrillo M, Baker L, Meszaros A, Dram A, Remy KE. Minerva Pediatr (Torino). 2023 Jun 16. doi: 10.23736/S2724-5276.23.07279-8. Online ahead of print. PMID: 37335186

Notes from the Field: Comparison of COVID-19 Mortality Rates Among Adults Aged ≥65 Years Who Were Unvaccinated and Those Who Received a Bivalent Booster Dose Within the Preceding 6 Months - 20 U.S. Jurisdictions, September 18, 2022-April 1, 2023.
Johnson AG, Linde L, Payne AB, Ali AR, Aden V, Armstrong B, Armstrong B, Auche S, Bayoumi NS, Bennett S, Boulton R, Chang C, Collingwood A, Cueto K, Davidson SL, Du Y, Fleischauer A, Force V, Frank D, Hamilton R, Harame K, Harrington P, Hicks L, Hodis JD, Hoskins M, Jones A, Kanishka F, Kaur R, Kirkendall S, Khan SI, Klioueva A, Link-Gelles R, Lyons S, Mansfield J, Markelz A, Masarik J 3rd, Mendoza E, Morris K, Omoike E, Paritala S, Patel K, Pike M, Pompa XP, Praetorius K, Rammouni N, Razzaghi H, Riggs A, Shi M, Sigalo N, Stanislawski E, Tilakaratne BP, Turner KA, Wiedeman C, Silk BJ, Scobie HM. MMWR Morb Mortal Wkly Rep. 2023 Jun 16;72(24):667-669. doi: 10.15585/mmwr.mm7224a6. PMID: 37319029

VaccineChain: A checkpoint assisted scalable blockchain based secure vaccine supply chain with selective revocation.
Mishra R, Ramesh D, Edla DR, Qi L. J Ind Inf Integr. 2023 Jun 20:100485. doi: 10.1016/j.jii.2023.100485. Online ahead of print. PMID: 37359315

Spontaneous reporting of adverse reactions associated with the COVID-19 vaccine in health care professionals: A descriptive observational study conducted in a Portuguese hospital.
Teófilo VSG, Pinho PRA, Cordeiro GJ, Saldanha NAF, Matos PMM, Ribeiro RAM, Moreira SM, Miller MSF, Dias ARM, Couto MFR, Norton PMPNS. Porto Biomed J. 2023 Jun 26;8(3):e219. doi: 10.1097/j.pbj.0000000000000219. eCollection 2023 May-Jun. PMID: 37383526

Increased vaccine sensitivity of an emerging SARS-CoV-2 variant.
Lewnard JA, Hong V, Kim JS, Shaw SF, Lewin B, Takhar H, Lipsitch M, Tartof SY. Nat Commun. 2023 Jun 29;14(1):3854. doi: 10.1038/s41467-023-39567-2. PMID: 37386005

Interpretation of active-control randomised trials: the case for a new analytical perspective involving averted events.
Dunn DT, Stirrup OT, McCormack S, Glidden DV. BMC Med Res Methodol. 2023 Jun 26;23(1):149. doi: 10.1186/s12874-023-01970-0. PMID: 37365584

Longitudinal analysis of memory TFH cells and antibody response following CoronaVac vaccination.
Zhou P, Cao C, Ji T, Zheng T, Dai Y, Liu M, Jiang J, Sun D, Bai Z, Lu X, Gong F. JCI Insight. 2023 Jun 29:e168437. doi: 10.1172/jci.insight.168437. Online ahead of print. PMID: 37384407

Challenges of conducting an international observational study to assess immunogenicity of multiple COVID-19 vaccines.
Sardana R, Kingebeni PM, Snc WA, Beavogui AH, Biampata JL, Dabitao D, de Blas PDCG, Gayedyu-Dennis D, Haidara MC, Jargalsaikhan G, Nyuangar G, Purnama A, Palacios GR, Samake S, Tounkara M, Weyers S, Zulkhuu D, Hunsberger S, Ridzon R. PLOS Glob Public Health. 2023 Jun 20;3(6):e0001918. doi: 10.1371/journal.pgph.0001918. eCollection 2023. PMID: 37339111

CoVigator-A Knowledge Base for Navigating SARS-CoV-2 Genomic Variants.
Bukur T, Riesgo-Ferreiro P, Sorn P, Gudimella R, Hausmann J, Rösler T, Löwer M, Schrörs B, Sahin U. Viruses. 2023 Jun 17;15(6):1391. doi: 10.3390/v15061391. PMID: 37376690

Impact of Coronavirus Disease 2019 and Vaccination Attitudes on Alpha-1 Antitrypsin Deficiency.
Hay MA, Holm KE, McCathern J, Sandhaus RA, Strange C. Chronic Obstr Pulm Dis. 2023 Jun 26. doi: 10.15326/jcopdf.2023.0406. Online ahead of print. PMID: 37363861

Comparative Study on Two COVID-19 Outbreaks at a Long-Term Mental Health Facility in Korea in 2020 and 2022.
Kim J, Choi G, Oh J, Park K, Yoo SJ. Medicina (Kaunas). 2023 Jun 18;59(6):1170. doi: 10.3390/medicina59061170. PMID: 37374374

A broad-spectrum macrocyclic peptide inhibitor of the SARS-CoV-2 spike protein.
Thijssen V, Hurdiss DL, Debski-Antoniak OJ, Spence MA, Franck C, Norman A, Aggarwal A, Mokiem NJ, van Dongen DAA, Vermeir SW, Liu M, Li W, Chatziandreou M, Donselaar T, Du W, Drulyte I, Bosch BJ,

Snijder J, Turville SG, Payne RJ, Jackson CJ, van Kuppeveld FJM, Jongkees SAK. Proc Natl Acad Sci U S A. 2023 Jun 27;120(26):e2303292120. doi: 10.1073/pnas.2303292120. Epub 2023 Jun 20. PMID: 37339194

Politics matters for individual attitudes toward vaccine donation: cross-national evidence from the United States and Taiwan.
Hsiao Y, Lin FY, Sheen GC, Wang CH. Global Health. 2023 Jun 20;19(1):40. doi: 10.1186/s12992-023-00940-x. PMID: 37340401

Clinical efficacy of the fourth dose of the BNT162b2 vaccine in maintenance dialysis patients.
Cohen-Hagai K, Hornik-Lurie T, Benchetrit S, Nacasch N, Grupper A, Einbinder Y, Wand O, Shashar M. J Nephrol. 2023 Jun 16. doi: 10.1007/s40620-023-01667-z. Online ahead of print. PMID: 37326951

Development of ANCA-associated vasculitis followed by SARS-CoV-2 vaccination in a patient with HLA-DRB1*09:01 allele.
Kawamura T, Nakazawa D, Nishio S, Isozaki T, Komatsumoto M, Atsumi T. Mod Rheumatol Case Rep. 2023 Jun 19;7(2):426-430. doi: 10.1093/mrcr/rxac093. PMID: 36610742

Jumping the Queue:Willingness to Pay for Faster Access to COVID-19 Vaccines in Seven European Countries.
Neumann-Böhme S, Sabat I, Brinkmann C, Attema AE, Stargardt T, Schreyögg J, Brouwer W. Pharmacoeconomics. 2023 Jun 21. doi: 10.1007/s40273-023-01284-5. Online ahead of print. PMID: 37344725

Facing the Challenges in the COVID-19 Pandemic Era: From Standard Treatments to the Umbilical Cord-Derived Mesenchymal Stromal Cells as a New Therapeutic Strategy.
Russo E, Corrao S, Di Gaudio F, Alberti G, Caprnda M, Kubatka P, Kruzliak P, Miceli V, Conaldi PG, Borlongan CV, La Rocca G. Cells. 2023 Jun 19;12(12):1664. doi: 10.3390/cells12121664. PMID: 37371134

Letter to the Editor From Zhang et al: "Effect of Inactivated and mRNA COVID-19 Vaccination on Thyroid Function Among Patients Treated for Hyperthyroidism".
Zhang Y, Zhu S, Gao Y. J Clin Endocrinol Metab. 2023 Jun 16;108(7):e497-e498. doi: 10.1210/clinem/dgad094. PMID: 36848137

Parent-reported provider recommendation of HPV vaccination among minority adolescents before and during the COVID-19 pandemic: Findings from the National Immunization Survey-Teen, 2019-2021.
Ejezie CL, Cuccaro P, Durand C, Savas L, Shegog R. Prev Med Rep. 2023 Oct;35:102286. doi: 10.1016/j.pmedr.2023.102286. Epub 2023 Jun 21. PMID: 37361924

Hepatitis B reactivation: A possible cause of coronavirus disease 2019 vaccine induced hepatitis.
Wu HY, Su TH, Liu CJ, Yang HC, Tsai JH, Wei MH, Chen CC, Tung CC, Kao JH, Chen PJ. J Formos Med Assoc. 2023 Jun 20:S0929-6646(23)00235-8. doi: 10.1016/j.jfma.2023.06.007. Online ahead of print. PMID: 37349170

Operation Remote Immunity: exploring the impact of a service-learning elective in remote Indigenous communities.

Mikhail H, Button B, LeBlanc J, Cervin C, Cameron E. BMC Med Educ. 2023 Jun 20;23(1):456. doi: 10.1186/s12909-023-04434-7. PMID: 37340413

Bivalent mRNA vaccine effectiveness against SARS-CoV-2 variants of concern.
Kumari M, Su SC, Liang KH, Lin HT, Lu YF, Chen KC, Chen WY, Wu HC. J Biomed Sci. 2023 Jun 28;30(1):46. doi: 10.1186/s12929-023-00936-0. PMID: 37380988

Risk prediction of covid-19 related death or hospital admission in adults testing positive for SARS-CoV-2 infection during the omicron wave in England (QCOVID4): cohort study.
Hippisley-Cox J, Khunti K, Sheikh A, Nguyen-Van-Tam JS, Coupland CAC. BMJ. 2023 Jun 21;381:e072976. doi: 10.1136/bmj-2022-072976. PMID: 37343968

Impact of Influenza Vaccination on the Burden of Severe Influenza in the Elderly: Spain, 2017-2020.
Mazagatos C, Delgado-Sanz C, Milagro A, Liébana-Rodríguez M, Larrauri A. Vaccines (Basel). 2023 Jun 17;11(6):1110. doi: 10.3390/vaccines11061110. PMID: 37376499

Effectiveness of a fourth dose of mRNA-1273 against COVID-19 among older adults in the United States: Interim results from an observational cohort study.
Ku JH, Sy LS, Qian L, Ackerson BK, Luo Y, Tubert JE, Lee GS, Florea A, Bruxvoort KJ, Xie F, Qiu S, Chavers S, Talarico CA, Tseng HF. Vaccine. 2023 Jun 29;41(29):4212-4219. doi: 10.1016/j.vaccine.2023.06.016. Epub 2023 Jun 5. PMID: 37301708

Clinical features of COVID-19 among patients with end-stage renal disease on hemodialysis in the context of high vaccination coverage during the omicron surge period: a retrospective cohort study.
Beck NS, Song S, Park T, Hong SH, Jeong-Eun J, Kim KH, Im JI, Hong SY. BMC Nephrol. 2023 Jun 27;24(1):191. doi: 10.1186/s12882-023-03219-w. PMID: 37370006

Low levels of neutralizing antibodies against XBB Omicron subvariants after BA.5 infection.
Yang J, Hong W, Lei H, He C, Lei W, Zhou Y, Zhao T, Alu A, Ma X, Li J, Yang L, Wang Z, Wang W, Lu G, Shen G, Lu S, Wu G, Shi H, Wei X. Signal Transduct Target Ther. 2023 Jun 19;8(1):252. doi: 10.1038/s41392-023-01495-4. PMID: 37336889

Effectiveness of inactivated COVID-19 vaccine against the severity of Omicron variant.
Wang H, Liu L, Wu T. Front Med. 2023 Jun 27. doi: 10.1007/s11684-023-0991-0. Online ahead of print. PMID: 37365449

Medical outcomes of children with neurodevelopmental disorders after SARS-CoV-2 vaccination: A six-month follow-up study.
Wang LJ, Tsai CS, Chou WJ, Li CJ, Lee SY, Chen YC, Lin IC. Vaccine. 2023 Jun 29;41(29):4267-4273. doi: 10.1016/j.vaccine.2023.05.067. Epub 2023 May 29. PMID: 37271705

Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration.
Follmann D, O'Brien MP, Fintzi J, Fay MP, Montefiori D, Mateja A, Herman GA, Hooper AT, Turner KC, Chan KC, Forleo-Neto E, Isa F, Baden LR, El Sahly HM, Janes H, Doria-Rose N, Miller J, Zhou H, Dang W, Benkeser D, Fong Y, Gilbert PB, Marovich M, Cohen MS. Nat Commun. 2023 Jun 17;14(1):3605. doi: 10.1038/s41467-023-39292-w. PMID: 37330602

Viral persistence in children infected with SARS-CoV-2: current evidence and future research strategies.
Buonsenso D, Martino L, Morello R, Mariani F, Fearnley K, Valentini P. Lancet Microbe. 2023 Jun 26:S2666-5247(23)00115-5. doi: 10.1016/S2666-5247(23)00115-5. Online ahead of print. PMID: 37385286

Prospective interpretation of Covid vaccines. A cross sectional study, Ordu province experience.
Çoruh Akyol B, Turgut B, İşcanlı MD, Kaya M, Çankaya S, Enginyurt Ö. Hum Vaccin Immunother. 2023 Jun 29:2222649. doi: 10.1080/21645515.2023.2222649. Online ahead of print. PMID: 37381762

NAUNEHAL; Integrated immunization and MNCH interventions: A quasi-experimental study-Protocol.
Ataullahjan A, Khan A, Islam M, Tahir R, Anwar S, Ahmed I, Nauman A, Bhutta ZA. PLoS One. 2023 Jun 29;18(6):e0287722. doi: 10.1371/journal.pone.0287722. eCollection 2023. PMID: 37384671

Apobec3A Deamination Functions Are Involved in Antagonizing Efficient Human Adenovirus Replication and Gene Expression.
Göttig L, Weiß C, Stubbe M, Hanrieder L, Hofmann S, Grodziecki A, Stadler D, Carpentier A, Protzer U, Schreiner S. mBio. 2023 Jun 27;14(3):e0347822. doi: 10.1128/mbio.03478-22. Epub 2023 May 8. PMID: 37154747

A Single Oral Immunization with a Replication-Competent Adenovirus-Vectored Vaccine Protects Mice from Influenza Respiratory Infection.
Goffin E, Du X, Hemmi S, Machiels B, Gillet L. J Virol. 2023 Jun 20:e0013523. doi: 10.1128/jvi.00135-23. Online ahead of print. PMID: 37338377

Two Novel Adenovirus Vectors Mediated Differential Antibody Responses via Interferon-α and Natural Killer Cells.
Zou P, Zhang P, Deng Q, Wang C, Luo S, Zhang L, Li C, Li T. Microbiol Spectr. 2023 Jun 22:e0088023. doi: 10.1128/spectrum.00880-23. Online ahead of print. PMID: 37347197

Site specific N- and O-glycosylation mapping of the spike proteins of SARS-CoV-2 variants of concern.
Shajahan A, Pepi LE, Kumar B, Murray NB, Azadi P. Sci Rep. 2023 Jun 21;13(1):10053. doi: 10.1038/s41598-023-33088-0. PMID: 37344512

Utilisation of services along the continuum of maternal healthcare during the COVID-19 pandemic in Lubumbashi, DRC: findings from a cross-sectional household survey of women.
Galle A, Kavira G, Semaan A, Malonga Kaj F, Benova L, Ntambue A. BMJ Open. 2023 Jun 26;13(6):e069409. doi: 10.1136/bmjopen-2022-069409. PMID: 37369398

High SARS-CoV-2 seroprevalence in Lagos, Nigeria with robust antibody and cellular immune responses.
Akanmu S, Herrera BB, Chaplin B, Ogunsola S, Osibogun A, Onawoga F, John-Olabode S, Akase IE, Nwosu A, Hamel DJ, Chang CA, Kanki PJ. J Clin Virol Plus. 2023 Aug;3(3):100156. doi: 10.1016/j.jcvp.2023.100156. Epub 2023 Jun 24. PMID: 37388808

A Case of Concurrent Acute Macular Neuroretinopathy and Paracentral Acute Middle Maculopathy Following Pfizer-BioNTech COVID-19 Vaccination.
Menteş J, Nalçacı S, Değirmenci C. Turk J Ophthalmol. 2023 Jun 21;53(3):186-191. doi: 10.4274/tjo.galenos.2023.65118. PMID: 37345327

Longitudinal Follow-Up of the Immunity to SARS-CoV-2 in Health Care Workers in Argentina: Persistence of Humoral Response and Neutralizing Capacity after Sputnik V Vaccination.
Castro EF, Acosta J, Moriena L, Rios Medrano M, Tejerina Cibello M, Codino E, Taborda MÁ, Álvarez DE, Cavatorta AL. mSphere. 2023 Jun 22;8(3):e0066222. doi: 10.1128/msphere.00662-22. Epub 2023 Apr 18. PMID: 37070983

Assessment of SARS-CoV-2 neutralizing antibody titers in breastmilk from convalescent and vaccinated mothers.
Bäuerl C, Zulaica J, Rusu L, Moreno AR, Pérez-Cano FJ, Lerin C, Mena-Tudela D, Aguilar-Camprubí L, Parra-Llorca A, Martínez-Costa C, Geller R, Collado MC; MilkCORONA study team. iScience. 2023 Jun 16;26(6):106802. doi: 10.1016/j.isci.2023.106802. Epub 2023 May 4. PMID: 37197591

The role of children in household transmission of SARS-CoV-2 across four waves of the pandemic.
Fuller TL, Bastos L, Sá Carvalho M, Cristina Resende P, Damasceno L, Gonçalves Cruz O, Medeiros F, Calvet G, Guaraldo L, Nielsen-Saines K, Whitworth J, Smith C, Siqueira M, Brasil P. J Pediatric Infect Dis Soc. 2023 Jun 16:piad044. doi: 10.1093/jpids/piad044. Online ahead of print. PMID: 37327193

Vaccination Ameliorates Cellular Inflammatory Responses in SARS-CoV-2 Breakthrough Infections.
Huapaya JA, Higgins J, Kanth S, Demirkale CY, Gairhe S, Aboye EA, Regenold D, Sahagun SJ, Pastor G, Swaim D, Dewar R, Rehman T, Highbarger HC, Lallemand P, Laverdure S, Adelsberger J, Rupert A, Li W, Krack J, Teferi G, Kuruppu J, Strich JR, Davey R, Childs R, Chertow D, Kovacs JA, Barnett C, Torabi-Parizi P, Suffredini AF; COVID-ARC Study Group. J Infect Dis. 2023 Jun 28;228(1):46-58. doi: 10.1093/infdis/jiad045. PMID: 36801946

Racial/Ethnic Differences in the Predictive Utility of Psychosocial Determinants of COVID-19 Vaccination Intentions.
Pierce JD, Segundo J, Derrick JL. Am J Health Promot. 2023 Jun 27:8901171231186315. doi: 10.1177/08901171231186315. Online ahead of print. PMID: 37369621

Increasing Antibody Responses to Five Doses of SARS-CoV-2 mRNA Vaccine in Lung Transplant Patients.
van Gemert J, Steenberg F, van Leer-Buter C, Kerstjens H, Steenhuis W, Akkerman O, Verschuuren E, Gan T. J Clin Med. 2023 Jun 18;12(12):4125. doi: 10.3390/jcm12124125. PMID: 37373817

Trends in SARS-CoV-2 infection and vaccination in school staff, students and their household members from 2020 to 2022 in Wales, UK: an electronic cohort study.
Lowthian E, Abbasizanjani H, Bedston S, Akbari A, Cowley L, Fry R, Owen RK, Hollinghurst J, Rudan I, Beggs J, Marchant E, Torabi F, Lusignan S, Crick T, Moore G, Sheikh A, Lyons RA. J R Soc Med. 2023 Jun 22:1410768231181268. doi: 10.1177/01410768231181268. Online ahead of print. PMID: 37347268

Prevaccination Glucose Time in Range Correlates With Antibody Response to SARS-CoV-2 Vaccine in Type 1 Diabetes.
Alhamar G, Briganti S, Maggi D, Viola V, Faraj M, Zannella C, Galdiero M, Franci G, Fusco C, Isgrò C, Leanza G, Malandrucco I, Spinelli A, Tramontana F, Iaria D, Tortoriello R, Pieralice S, Rosati M, Matarese G, Pozzilli P, Galgani M, Strollo R. J Clin Endocrinol Metab. 2023 Jun 16;108(7):e474-e479. doi: 10.1210/clinem/dgad001. PMID: 36611249

Effectiveness of inactivated COVID-19 vaccines against SARS-CoV-2 infections among healthcare personnel in Pakistan: a test-negative case-control study.
Khan UI, Niaz M, Azam I, Hasan Z, Hassan I, Mahmood SF, Ali A. BMJ Open. 2023 Jun 27;13(6):e071789. doi: 10.1136/bmjopen-2023-071789. PMID: 37369396

Evaluation of severe acute respiratory syndrome coronavirus 2 monoclonal antibodies in high-risk solid organ transplant recipients across three major coronavirus disease 2019 variant waves.
Zeitler K, Piccicacco N, O'Neal M, Montero J, Myers A, Strebig D, Nestler S, Anger LB, Kim K. Transpl Infect Dis. 2023 Jun 28:e14095. doi: 10.1111/tid.14095. Online ahead of print. PMID: 37378536

Rapid Establishment of a Biospecimen Resource To Study the Global Impact of COVID-19 Vaccines.
Berliner KE, Ezzelle T, Klenk T, Dunn G, Sischo J, Campbell D, McKee KT. Microbiol Spectr. 2023 Jun 27:e0211723. doi: 10.1128/spectrum.02117-23. Online ahead of print. PMID: 37367491

Adverse effects of COVID-19 vaccination in patients with Transfusion Dependent Thalassemia (TDT): an observational study from a tertiary care centre in Punjab, India.
Kakkar S, Jain E, Jain A, Dewan P. Acta Haematol. 2023 Jun 16. doi: 10.1159/000531448. Online ahead of print. PMID: 37331336

Safety of COVID-19 booster dose: is the juice worth the squeeze?
Madhi SA, Izu A. Lancet Infect Dis. 2023 Jun 20:S1473-3099(23)00296-7. doi: 10.1016/S1473-3099(23)00296-7. Online ahead of print. PMID: 37352876

Adverse Events and Serological Responses After SARS-CoV-2 Vaccination in Individuals With Inflammatory Bowel Disease.
Markovinović A, Quan J, Herauf M, Hracs L, Windsor JW, Sharifi N, Coward S, Caplan L, Gorospe J, Ernest-Suarez K, Ma C, Panaccione R, Ingram RJM, Kanji JN, Tipples G, Holodinsky JK, Bernstein CN, Mahoney DJ, Bernatsky S, Benchimol EI, Kaplan GG; STOP COVID-19 in IBD Research Group; STOP COVID-19 in IBD Research Group. Am J Gastroenterol. 2023 Jun 26. doi: 10.14309/ajg.0000000000002337. Online ahead of print. PMID: 37216598

An Advax-CpG55.2™ adjuvanted recombinant spike protein vaccine protects cynomolgus macaques from a homologous SARS-CoV-2 virus challenge.
Honda-Okubo Y, Li L, André G, Leong KH, Howerth EW, Bebin-Blackwell AG, Ross TM, Petrovsky N. Vaccine. 2023 Jun 19:S0264-410X(23)00748-X. doi: 10.1016/j.vaccine.2023.06.063. Online ahead of print. PMID: 37355452

Diminished responses to mRNA-based SARS-CoV-2 vaccines in individuals with rheumatoid arthritis on immune modifying therapies.
Klebanoff SD, Rodda LB, Morishima C, Wener MH, Yuzefpolskiy Y, Bettelli E, Buckner JH, Speake C, Pepper M, Campbell DJ. JCI Insight. 2023 Jun 20:e168663. doi: 10.1172/jci.insight.168663. Online ahead of print. PMID: 37338983

Attenuated immunogenicity of SARS-CoV-2 vaccines and risk factors in stem cell transplant recipients: A meta-analysis.
Meejun T, Srisurapanont K, Manothummetha K, Thongkam A, Mejun N, Chuleerarux N, Sanguankeo A, Phongkhun K, Leksuwankun S, Thanakitcharu J, Lerttiendamrong B, Langsiri N, Torvorapanit P,

Worasilchai N, Plongla R, Hirankarn N, Nematollahi S, Permpalung N, Moonla C, Kates OS. Blood Adv. 2023 Jun 30:bloodadvances.2023010349. doi: 10.1182/bloodadvances.2023010349. Online ahead of print. PMID: 37389818

Role satisfaction among community volunteers working in mass COVID-19 vaccination clinics, Waterloo Region, Canada.
Tetui M, Tennant R, Patten A, Giilck B, Burns CM, Waite N, Grindrod K. BMC Public Health. 2023 Jun 21;23(1):1199. doi: 10.1186/s12889-023-15597-9. PMID: 37344794

Adverse events following immunisation (AEFI) of COVISHIELD vaccination among healthcare workers in Ghana.
Marfoh K, Samba A, Okyere E, Acheampong F, Owusu E, Darko DNA, Zakariah J, Mensa H, Aidoo E, Mohammed Y. BMJ Open. 2023 Jun 28;13(6):e061643. doi: 10.1136/bmjopen-2022-061643. PMID: 37380201

Trends in Laboratory-Confirmed SARS-CoV-2 Reinfections and Associated Hospitalizations and Deaths Among Adults Aged ≥18 Years - 18 U.S. Jurisdictions, September 2021-December 2022.
Ma KC, Dorabawila V, León TM, Henry H, Johnson AG, Rosenberg E, Mansfield JA, Midgley CM, Plumb ID, Aiken J, Khanani QA, Auche S, Bayoumi NS, Bennett SA, Bernu C, Chang C, Como-Sabetti KJ, Cueto K, Cunningham S, Eddy M, Falender RA, Fleischauer A, Frank DM, Harrington P, Hoskins M, Howsare A, Ingaiza LM, Islam AS, Jensen SA, Jones JM, Kambach G, Kanishka F, Levin Y, Masarik JF 3rd, Meyer SD, Milroy L, Morris KJ, Olmstead J, Olsen NS, Omoike E, Patel K, Pettinger A, Pike MA, Reed IG, Slocum E, Sutton M, Tilakaratne BP, Vest H, Vostok J, Wang JS, Watson-Lewis L, Wienkes HN, Hagen MB, Silk BJ, Scobie HM. MMWR Morb Mortal Wkly Rep. 2023 Jun 23;72(25):683-689. doi: 10.15585/mmwr.mm7225a3. PMID: 37347715

Targets and cross-reactivity of human T cell recognition of common cold coronaviruses.
Tarke A, Zhang Y, Methot N, Narowski TM, Phillips E, Mallal S, Frazier A, Filaci G, Weiskopf D, Dan JM, Premkumar L, Scheuermann RH, Sette A, Grifoni A. Cell Rep Med. 2023 Jun 20;4(6):101088. doi: 10.1016/j.xcrm.2023.101088. Epub 2023 May 29. PMID: 37295422

Comprehensive landscape of the miRNA-regulated prognostic marker LAYN with immune infiltration and stemness in pan-cancer.
Jiawen W, Jinfu W, Jianyong L, Yaoguang Z, Jianye W. J Cancer Res Clin Oncol. 2023 Jun 19. doi: 10.1007/s00432-023-04986-7. Online ahead of print. PMID: 37335337

Long-term safety of COVID vaccination in individuals with idiopathic inflammatory myopathies: results from the COVAD study.
Doskaliuk B, Ravichandran N, Sen P, Day J, Joshi M, Nune A, Nikiphorou E, Saha S, Tan AL, Shinjo SK, Ziade N, Velikova T, Milchert M, Jagtap K, Parodis I, Gracia-Ramos AE, Cavagna L, Kuwana M, Knitza J, Chen YM, Makol A, Agarwal V, Patel A, Pauling JD, Wincup C, Barman B, Tehozol EAZ, Serrano JR, La Torre IG, Colunga-Pedraza IJ, Merayo-Chalico J, Chibuzo OC, Katchamart W, Goo PA, Shumnalieva R, Hoff LS, Kibbi LE, Halabi H, Vaidya B, Shaharir SS, Hasan ATMT, Dey D, Gutiérrez CET, Caballero-Uribe CV, Lilleker JB, Salim B, Gheita T, Chatterjee T, Distler O, Saavedra MA; COVAD study group; Chinoy H, Agarwal V, Aggarwal R, Gupta L. Rheumatol Int. 2023 Jun 23. doi: 10.1007/s00296-023-05345-y. Online ahead of print. PMID: 37351634

Durable Anti-SARS-CoV-2 Antibody Response after mRNA-1273 Booster in Peritoneal Dialysis Patients during the Omicron Wave.
Beilhack G, Monteforte R, Frommlet F, Reindl-Schwaighofer R, Strassl R, Vychytil A. Vaccines (Basel). 2023 Jun 19;11(6):1121. doi: 10.3390/vaccines11061121. PMID: 37376510

New-Onset Fulminant Type 1 Diabetes Following SARS-CoV-2 Protein Subunit Vaccine: A Case Report and Literature Review.
Huang L, Liang M, He Y. J Korean Med Sci. 2023 Jun 19;38(24):e209. doi: 10.3346/jkms.2023.38.e209. PMID: 37337812

Synergistic Strategies to Accelerate the Development of Function-Promoting Therapies: Lessons From Operation Warp Speed and Oncology Drug Development.
Correa-de Araujo R, Evans WJ, Fielding RA, Krishnan V, Carter RH, Appleby J, Guralnik J, Klickstein LB, Marks P, Moore AA, Peschin S, Bhasin S. J Gerontol A Biol Sci Med Sci. 2023 Jun 16;78(Supplement_1):94-100. doi: 10.1093/gerona/glad028. PMID: 37325963

A mutation in the coronavirus nsp13-helicase impairs enzymatic activity and confers partial remdesivir resistance.
Grimes SL, Choi YJ, Banerjee A, Small G, Anderson-Daniels J, Gribble J, Pruijssers AJ, Agostini ML, Abu-Shmais A, Lu X, Darst SA, Campbell E, Denison MR. mBio. 2023 Jun 20:e0106023. doi: 10.1128/mbio.01060-23. Online ahead of print. PMID: 37338298

Immune response after vaccination using inactivated vaccine for coronavirus disease 2019.
Sun Y, Kang H, Zhao Y, Cui K, Wu X, Huang S, Liang C, Wang W, Cao H, Zhang X, Shao F. Chin Med J (Engl). 2023 Jun 20;136(12):1497-1499. doi: 10.1097/CM9.0000000000002707. Epub 2023 May 8. PMID: 37154087

Comment on immunity to COVID-19 vaccination in patients with liver disease and transplant recipients.
Kleebayoon A, Wiwanitkit V. Hepatol Commun. 2023 Jun 22;7(7):e00189. doi: 10.1097/HC9.0000000000000189. eCollection 2023 Jul 1. PMID: 37347228

[Cryptogenic new-onset super-refractory status epilepticus following SARS-CoV-2 vaccination. A case report].
Villagrán-Sancho D, Luque-Ambrosiani AC, Mayorga-Morón C, Gómez-Fernández FJ, Arzalluz-Luque J, Castela-Murillo A, Hernández-Ramos FJ, Jiménez-Hernández MD, Palomino-García A. Rev Neurol. 2023 Jun 16;76(12):399-402. doi: 10.33588/rn.7612.2022374. PMID: 37303102

Reduction of SARS-CoV-2 intra-household child-to-parent transmission associated with ventilation: results from a case-control study.
Galmiche S, Charmet T, Madec Y, Rakover A, Schaeffer L, Chény O, Omar F, Martin S, Mailles A, Carrat F, Fontanet A. BMC Public Health. 2023 Jun 26;23(1):1240. doi: 10.1186/s12889-023-16144-2. PMID: 37365557

Hepatic and pulmonary involvement in a patient with PR3-ANCA vasculitis following SARS-CoV-2 vaccination: A case report.
Tonutti A, Simonetta E, Stainer A, Suigo G, De Santis M, Selmi C, Masetti C, Lleo A, Terracciano LM, Aliberti S, Amati F. Mod Rheumatol Case Rep. 2023 Jun 19;7(2):440-443. doi: 10.1093/mrcr/rxad005. PMID: 36695552

BNT162b2 Vaccination after SARS-CoV-2 Infection Changes the Dynamics of Total and Neutralizing Antibodies against SARS-CoV-2: A 6-Month Prospective Cohort Study.
Hernández-Bello J, Sierra-García-de-Quevedo JJ, Morales-Núñez JJ, Santoscoy-Ascencio G, Díaz-Pérez SA, Gutiérrez-Brito JA, Muñoz-Valle JF. Vaccines (Basel). 2023 Jun 20;11(6):1127. doi: 10.3390/vaccines11061127. PMID: 37376516

Multicomponent intranasal adjuvant for mucosal and durable systemic SARS-CoV-2 immunity in young and aged mice.
Jangra S, Landers JJ, Laghlali G, Rathnasinghe R, Warang P, Park SC, O'Konek JJ, Singh G, Janczak KW, García-Sastre A, Arya N, Karadag D, Baker JR Jr, Schotsaert M, Wong PT. NPJ Vaccines. 2023 Jun 29;8(1):96. doi: 10.1038/s41541-023-00691-1. PMID: 37386041

Age-associated B cells predict impaired humoral immunity after COVID-19 vaccination in patients receiving immune checkpoint blockade.
Yam-Puc JC, Hosseini Z, Horner EC, Gerber PP, Beristain-Covarrubias N, Hughes R, Lulla A, Rust M, Boston R, Ali M, Fischer K, Simmons-Rosello E, O'Reilly M, Robson H, Booth LH, Kahanawita L, Correa-Noguera A, Favara D, Ceron-Gutierrez L, Keller B, Craxton A, Anderson GSF, Sun XM, Elmer A, Saunders C, Bermperi A, Jose S, Kingston N, Mulroney TE, Piñon LPG; CITIID-NIHR COVID−19 BioResource Collaboration; Chapman MA, Grigoriadou S, MacFarlane M, Willis AE, Patil KR, Spencer S, Staples E, Warnatz K, Buckland MS, Hollfelder F, Hyvönen M, Döffinger R, Parkinson C, Lear S, Matheson NJ, Thaventhiran JED. Nat Commun. 2023 Jun 27;14(1):3292. doi: 10.1038/s41467-023-38810-0. PMID: 37369658

Clinical symptoms of SARS-CoV-2 breakthrough infection during the Omicron period in relation to baseline immune status and booster vaccination-A prospective multicentre cohort of health professionals (SURPRISE study).
Kohler P, Babouee Flury B, Güsewell S, Egger T, Leal O, Brucher A, Lemmenmeier E, Meier Kleeb D, Möller JC, Ortner M, Rieder P, Ruetti M, Schmid HR, Stocker R, Vuichard-Gysin D, Speer O, Wiggli B, Besold U, McGeer A, Risch L, Friedl A, Schlegel M, Vernazza P, Kahlert CR, Kuster SP; SURPRISE Study Group. Influenza Other Respir Viruses. 2023 Jun 19;17(6):e13167. doi: 10.1111/irv.13167. eCollection 2023 Jun. PMID: 37346094

Immune response enhancement with GLS-5310 DNA primary vaccine against SARS-CoV-2 followed by administration of an mRNA vaccine heterologous boost.
Kim WJ, Roberts CC, Song JY, Yoon JG, Seong H, Hyun HJ, Lee H, Gil A, Oh Y, Park JE, Lee JE, Jeon B, Kane D, Spruill S, Kudchodkar SB, Muthumani K, Park YK, Kwon I, Maslow JN. Vaccine. 2023 Jun 29;41(29):4206-4211. doi: 10.1016/j.vaccine.2023.06.013. Epub 2023 Jun 6. PMID: 37296017

Booster effect of the third dose of SARS-CoV-2 mRNA vaccine in Japanese kidney transplant recipients.
Kawabe M, Kuroda T, Yamamoto I, Kobayashi A, Ohki Y, Hayashi A, Urabe F, Miki J, Yamada H, Kimura T, Matsuo N, Tanno Y, Horino T, Ohkido I, Yamamoto H, Yokoo T. Sci Rep. 2023 Jun 20;13(1):9976. doi: 10.1038/s41598-023-36998-1. PMID: 37340001

Memory B cell development elicited by mRNA booster vaccinations in the elderly.
Wang Z, Muecksch F, Raspe R, Johannsen F, Turroja M, Canis M, ElTanbouly MA, Santos GSS, Johnson B, Baharani VA, Patejak R, Yao KH, Chirco BJ, Millard KG, Shimeliovich I, Gazumyan A, Oliveira TY,

Bieniasz PD, Hatziioannou T, Caskey M, Nussenzweig MC. J Exp Med. 2023 Sep 4;220(9):e20230668. doi: 10.1084/jem.20230668. Epub 2023 Jun 27. PMID: 37368240

Respiratory syncytial virus and other respiratory virus infections in residents of homeless shelters - King County, Washington, 2019-2021.
McCulloch DJ, Rogers JH, Wang Y, Chow EJ, Link AC, Wolf CR, Uyeki TM, Rolfes MA, Mosites E, Sereewit J, Duchin JS, Sugg NK, Greninger AL, Boeckh MJ, Englund JA, Shendure J, Hughes JP, Starita LM, Roychoudhury P, Chu HY. Influenza Other Respir Viruses. 2023 Jun 19;17(6):e13166. doi: 10.1111/irv.13166. eCollection 2023 Jun. PMID: 37346095

Genetic regulators of sputum mucin concentration and their associations with COPD phenotypes.
Buren EV, Radicioni G, Lester S, O'Neal WK, Dang H, Kasela S, Garudadri S, Curtis JL, Han MK, Krishnan JA, Wan ES, Silverman EK, Hastie A, Ortega VE, Lappalainen T, Nawijn MC, Berge MVD, Christenson SA, Li Y, Cho MH, Kesimer M, Kelada SNP. PLoS Genet. 2023 Jun 23;19(6):e1010445. doi: 10.1371/journal.pgen.1010445. Online ahead of print. PMID: 37352370

Antiviral Activity against SARS-CoV-2 of Conformationally Constrained Helical Peptides Derived from Angiotensin-Converting Enzyme 2.
Quagliata M, Stincarelli MA, Papini AM, Giannecchini S, Rovero P. ACS Omega. 2023 Jun 13;8(25):22665-22672. doi: 10.1021/acsomega.3c01436. eCollection 2023 Jun 27. PMID: 37387789

Kounis syndrome in a patient following AstraZeneca coronavirus disease 2019 vaccination: a case report.
Farook AM, Priyankara D. J Med Case Rep. 2023 Jun 28;17(1):289. doi: 10.1186/s13256-023-04022-9. PMID: 37370178

The role of lung ultrasonography in the SARS-CoV-2 vaccines and variants era: a case report.
Cepeda JG, Esteves AL, Marín-Baselga R, Tung-Chen Y. Med Ultrason. 2023 Jun 26;25(2):237-238. doi: 10.11152/mu-4053. PMID: 37369051

Two cases of systemic lupus erythematosus after administration of severe acute respiratory syndrome coronavirus 2 vaccine.
Sakai M, Takao K, Mizuno M, Ando H, Kawashima Y, Kato T, Kubota S, Hirose T, Hirota T, Horikawa Y, Yabe D. Mod Rheumatol Case Rep. 2023 Jun 19;7(2):378-382. doi: 10.1093/mrcr/rxad008. PMID: 36715089

Stimulating solidarity to improve knowledge on medications used during pregnancy : A contribution from the ConcePTION project.
Hollestelle MJ, van der Graaf R, Sturkenboom MC, van Delden JJ. BMC Med Ethics. 2023 Jun 27;24(1):44. doi: 10.1186/s12910-023-00924-x. PMID: 37370079

Burden of disease attributable to unsafe drinking water, sanitation, and hygiene in domestic settings: a global analysis for selected adverse health outcomes.
Wolf J, Johnston RB, Ambelu A, Arnold BF, Bain R, Brauer M, Brown J, Caruso BA, Clasen T, Colford JM Jr, Mills JE, Evans B, Freeman MC, Gordon B, Kang G, Lanata CF, Medlicott KO, Prüss-Ustün A, Troeger C, Boisson S, Cumming O. Lancet. 2023 Jun 17;401(10393):2060-2071. doi: 10.1016/S0140-6736(23)00458-0. Epub 2023 Jun 5. PMID: 37290458

Patentes registradas en Patentscope

Estrategia de búqueda: *Vaccine in the title or abstract AND 20230616:20230630 as the publication date 43 records*

1.WO/2023/113094COVID-19 VACCINE COMPOSITION WITH INCREASED IMMUNOGENICITY
WO - 22.06.2023
Clasificación Internacional A61K 39/215 Nº de solicitud PCT/KR2021/095130 Solicitante CTC VAC CO.,LTD Inventor/a JUNG, Ho Kyoung
The present invention relates to a COVID-19 vaccine composition with increased immunogenicity, and more specifically, to an antigen composition comprising a Spike 1 (COVID-19) recombinant antigen protein and a receptor binding domain (RBD) recombinant antigen protein of the SARS-CoV-2 virus, and a COVID-19 vaccine composition with increased immunogenicity, the vaccine composition containing Montanide Gel as an immunostimulating agent. The COVID-19 vaccine composition according to the present invention was found to have increased antibody-forming ability (immunogenicity) compared to vaccine compositions not containing Montanide Gel, and vaccination with the COVID-19 vaccine composition according to the present invention was found to activate $CD4^{+}IL\text{-}5^{+}$ T cells and $CD4^{+}IL\text{-}17^{+}$ T cells and increase IFN-γ and IL-5 cytokine production. In addition, the vaccine composition according to the present invention was found to also exhibit high immunogenicity against South African variants and British variants of the COVID-19 virus, and thus can be utilized as a vaccine composition for preventing or treating COVID-19.

2.WO/2023/122731A LIVE ATTENUATED MUMPS VIRUS-BASED SARS-COV-2 VACCINE
WO - 29.06.2023
Clasificación Internacional A61K 39/215 Nº de solicitud PCT/US2022/082244 Solicitante OHIO STATE INNOVATION FOUNDATION Inventor/a LI, Jianrong
Disclosed herein are live attenuated recombinant mumps virus (rMuV)-based SARS-CoV-2 vaccines and methods for vaccinating a subject for COVID-19 using the disclosed vaccines. Advantages of MuV-based SARS-CoV-2 vaccine include a great safety record, ideal for infants and children, overcomes the pre-existing MuV immunity, no integration to host DNA, high expression level, high efficacy, long term (life-long) immunity, excellent genetic stability, well-established GMP vaccine manufacture, a quadrivalent vaccine for SARS-CoV-2, MeV, MuV, and rubella virus, protection against SARS-CoV-2 variants, human clinical trial experience, and the MMR vaccine is lyophilized and stored at refrigerator temperatures both before and after it is reconstituted, greatly reducing its cost.

3.WO/2023/109740INHALATION ADMINISTRATION DELIVERY SYSTEM OF RECOMBINANT ADENOVIRUS VECTOR VACCINE
WO - 22.06.2023
Clasificación Internacional A61K 35/761 Nº de solicitud PCT/CN2022/138331 Solicitante CANSINO BIOLOGICS INC. Inventor/a SHAO, Juan
Disclosed is an inhalation administration delivery system of a recombinant adenovirus vector vaccine. In the delivery system, an adenovirus vector is reformed and matched with a specific preparation prescription, and after being administered by means of inhalation, the vaccine can reach the lungs by means of nasal inhalation or mouth inhalation, so that a protective immune response including mucosal immunity is generated, the effective utilization rate of the vaccine is increased, the pre-existing immunity of an adenovirus is solved, and an effect of the vaccine is improved.

4.WO/2023/114639METHODS AND COMPOSITIONS RELATED TO VIRAL VACCINES WITH IMPROVED PROPERTIES

WO - 22.06.2023
Clasificación Internacional A61K 39/12 Nº de solicitud PCT/US2022/080688 Solicitante THE SCRIPPS RESEARCH INSTITUTE Inventor/a HE, Linling
The present invention provides methods for producing scaffolded (e.g., nanoparticle presented) or non-scaffolded vaccines that are based on viral immunogenic proteins with a glycan shielded (e.g., HIV-1 Env). The vaccines thus generated demonstrate enhanced immunogenicity and responder frequency. The methods entail (1) enzymatic digestion of glycan chain on the surface of a viral trimer protein immunogen or a self-assembling nanoparticle vaccine displaying the viral immunogen (e.g., an HIV-1 UFO trimer), or (2) expression of a construct encoding the vaccine in an expression system lacking normal glycosylation function for human proteins. The methods can include an additional step of purifying the glycan shortened protein and/or formulating the protein into a vaccine composition. Also provided in the invention are vaccine compositions produced with the described methods. The invention further provides methods of using the vaccine compositions described herein (e.g., scaffolded or non-scaffolded HIV-1 vaccines) in various therapeutic applications, e.g., for preventing or treating viral infections.

5.WO/2023/118603IMPROVED VACCINIA VIRUS VECTORS
WO - 29.06.2023
Clasificación Internacional C07K 14/005 Nº de solicitud PCT/EP2022/087815 Solicitante STRATOSVIR LIMITED Inventor/a ULLMAN, Christopher
Disclosed herein are polynucleotides encoding fusion proteins, the fusion proteins comprising a vaccinia virus envelope protein, such as A13 or part thereof and at least one complement regulatory protein, such as CD35, CD55, CD59, CD46, CR1, Factor H, VCP, MOPICE, SPICE and CCPH, or a functional fragment thereof. Modified vaccinia virus vectors and vaccinia virus virions are also disclosed, as are therapeutic uses and methods for treatment of cancers and/or proliferative diseases or disorders.

6.WO/2023/118553STABLE EMULSIONS OF ANTIGENS
WO - 29.06.2023
Clasificación Internacional A61K 39/39 Nº de solicitud PCT/EP2022/087692 Solicitante INTERVET INTERNATIONAL B.V. Inventor/a PIEST, Martin
The present invention relates to the field of vaccinology, more specifically of veterinary vaccinology. In particular, the invention relates to an adjuvant composition comprising an emulsion of water, tocopherol or a pharmaceutically acceptable ester thereof, and a polyethoxyethylene cetostearyl ether as an emulsifier. Said adjuvant composition can be used for formulating a vaccine, particularly an emulsion vaccine, comprising a bacterial, parasitic, or viral antigen. The resulting vaccine composition can be used in a method of protecting a human or animal target against infection and/or disease caused by a pathogen, particularly caused by a bacterium, parasite or virus. The invention further relates to methods for the manufacture of such adjuvant compositions and for the manufacture of such vaccine composition.

7.WO/2023/109469PREPARATION METHOD FOR ALUMINUM OXYHYDROXIDE NANO ADJUVANT HAVING CONTROLLABLE SURFACE ENERGY
WO - 22.06.2023
Clasificación Internacional A61K 39/39 Nº de solicitud PCT/CN2022/134210 Solicitante DALIAN UNIVERSITY OF TECHNOLOGY Inventor/a SUN, Bingbing
A preparation method for an aluminum oxyhydroxide nano adjuvant having controllable surface energy, which is on the basis of a hydrothermal synthesis method. A specific orientation of crystal growth is controlled by changing a pH value of a precipitation system, and finally a purpose of controlling surface free energy of an AlOOH nanomaterial is achieved. The method is simple to operate, low in raw material price, and good in reaction product stability and repeatability. A prepared aluminum oxyhydroxide nano material is uniform in morphology and uniform in dispersion, and has a good prospect in vaccine

preparation and production. An AlOOH adjuvant-based vaccine formulation and an immune effector verification method are simple and high in operability, and a good policy is provided for engineering development and further clinical conversion of a vaccine preparation.

8.WO/2023/118426STABILISED LIQUID VACCINES OF LIVE VIRUSES
WO - 29.06.2023
Clasificación Internacional A61K 39/12 Nº de solicitud PCT/EP2022/087464 Solicitante INTERVET INTERNATIONAL B.V. Inventor/a KETS, Edwin
The present invention relates to liquid vaccine composition comprising a live virus and a natural deep-eutectic solvent (NADES) as the carrier. The carrier additionally comprises an additive selected from methionine and (hydroxy)ectoine. The additive is able to reduce the loss of virus titre over time, upon storage in a NADES-based liquid vaccine composition having up to 50 % w/w of water. Such compositions are less viscous which is favourable for the manufacture of the carrier, and the formulation and use of the liquid vaccine.

9.WO/2023/118394DNA VACCINE AGAINST LEISHMANIASIS
WO - 29.06.2023
Clasificación Internacional A61K 39/002 Nº de solicitud PCT/EP2022/087392 Solicitante INTERVET INTERNATIONAL B.V. Inventor/a ARAMUNI GONCALVES, Luciana
The present invention relates to the fields of veterinary medicine and virology and provides a vaccine against leishmaniasis. In particular, the invention relates to an isolated polynucleotide comprising (i) a first expression cassette comprising a nucleic acid encoding heat shock protein (hsp) 65, and (ii) a second expression cassette comprising a nucleic acid encoding LACK (Leishmania homologue of receptors for activated C kinase). In other embodiments, the invention relates to a DNA plasmid comprising the polynucleotide, a DNA vaccine for use in the treatment of leishmaniasis, and a method of immunizing a subject against an infection with leishmaniasis.

10.WO/2023/121264VACCINE COMPOSITION FOR SARS-COV-2 VARIANT, AND USE THEREOF
WO - 29.06.2023
Clasificación Internacional A61K 39/215 Nº de solicitud PCT/KR2022/020898 Solicitante EYEGENE INC. Inventor/a CHO, Yang Je
The present disclosure relates to a vaccine composition for preventing a SARS-CoV-2 variant, the composition comprising mRNA encoding an S antigen of a SARS-CoV-2 variant virus. A vaccine for preventing the SARS-CoV-2 variant according to the present disclosure exhibits excellent stability and high immunogenicity in vivo and is thus easy to store and use, and is expected to have an excellent preventive effect against COVID-19.

11.WO/2023/116413METHOD OF DEVELOPING A PEPTIDE-BASED VACCINE CONJUGATED WITH 1V209
WO - 29.06.2023
Clasificación Internacional A61K 39/39 Nº de solicitud PCT/CN2022/136832 Solicitante VERSITECH LIMITED Inventor/a HUANG, Jiandong
Provided are a composition comprising a peptide conjugated to a TLR agonist, including TLR7 agonist 1v209, and methods of using the composition. The methods comprise administering the peptide-based vaccine conjugate to a subject. The peptide-based vaccine conjugate inhibits tumor growth and induces antigen-specific B and T cell responses in a subject.

12.WO/2023/111262LYME DISEASE RNA VACCINE
WO - 22.06.2023
Clasificación Internacional A61P 31/04 Nº de solicitud PCT/EP2022/086341 Solicitante SANOFI Inventor/a PAVOT, Vincent

The present disclosure provides a Lyme disease vaccine, comprising a messenger RNA (mRNA) comprising an open reading frame (ORF) encoding at least one antigenic polypeptide derived from at least one bacteria of the genus *Borrelia*, and methods of eliciting an immune response by administering said vaccine.

13.WO/2023/110422VACCINE PREPARATION
WO - 22.06.2023
Clasificación Internacional A61K 39/12 Nº de solicitud PCT/EP2022/084011 Solicitante GRABUSCHNIG, Stefan Inventor/a GRABUSCHNIG, Stefan
A vaccine preparation to be administered intramuscularly without or at least minor adverse effects comprises in addition to a mRNA-vaccine at least one vasoconstrictive agent, such as epinephrine, levonorderfrine and norepinephrine.

14.WO/2023/120535VACCINE ADJUVANT AGENT CONTAINING POLYACRYLIC ACID POLYMER AND USE OF SAME
WO - 29.06.2023
Clasificación Internacional A61K 39/39 Nº de solicitud PCT/JP2022/046937 Solicitante TOKO YAKUHIN KOGYO CO., LTD. Inventor/a KAMISHITA, Taizou
The present disclosure provides a vaccine adjuvant agent which contains a high molecular weight polymer that comprises an acrylic acid as a constituent unit, while having a carboxyl group content of 60.0% by mass to 62.5% by mass.

15.WO/2023/109835VEGF-CRM197 RECOMBINANT FUSION PROTEIN VACCINE, AND PREPARATION METHOD THEREFOR AND USE THEREOF
WO - 22.06.2023
Clasificación Internacional C07K 1/22 Nº de solicitud PCT/CN2022/138799 Solicitante SHANGHAI HUIMMUTECH BIOTECHNOLOGY CO., LTD Inventor/a ZHANG, Wenyao
Provided in the present invention are a VEGF-CRM197 recombinant fusion protein vaccine, and a preparation method therefor and the use thereof. Specifically, provided in the present invention is that truncated VEGF, namely a VEGF1-107 antigen fragment, which loses the biological activity of VEGF but retains its immunogenicity, is fused with diphtheria toxin mutant CRM197 for recombinant expression to form a VEGF recombinant fusion protein. After being used in combination with a liquid adjuvant, the VEGF recombinant fusion protein can induce mice and rhesus monkeys to produce high-titer antibodies and block the binding of VEGF-A to a receptor thereof, thereby inhibiting the promotion effect of VEGF-A on the proliferation of vascular endothelial cells.

16.WO/2023/121036VACCINE COMPOSITION COMPRISING INACTIVATED PNEUMOCOCCAL MUTANT STRAIN
WO - 29.06.2023
Clasificación Internacional A61K 39/09 Nº de solicitud PCT/KR2022/019299 Solicitante ILDONG PHARMACEUTICAL CO., LTD. Inventor/a LEE, Dong Kwon
The present application relates to a vaccine composition comprising an inactivated pneumococcal mutant strain for prevention or treatment of pneumonia, wherein the inactivated pneumococcal mutant strain has a part or the entirety of the pep27 gene deleted.

17.WO/2023/113016EFFICIENT VACCINE
WO - 22.06.2023
Clasificación Internacional C12N 15/62 Nº de solicitud PCT/JP2022/046430 Solicitante VLP THERAPEUTICS JAPAN, INC. Inventor/a AKAHATA, Wataru
Provided herein is an isolated polynucleotide, which encodes structural proteins nsp1, nsp2, nsp3 and nsp4 and a polypeptide comprising an antigenic protein fused to a signal sequence, a transmembrane

domain and at least one peptide selected from CD4+ T cell epitopes and CD8+ T cell epitopes. The polynucleotide is useful for manufacturing a vaccine against virus infection, especially, COVID-19 infection, the treatment of a cancer and/or an inflammatory disease.

18.WO/2023/117742VACCINE COMPOSITIONS AND THEIR USE
WO - 29.06.2023
Clasificación Internacional A61K 39/12 Nº de solicitud PCT/EP2022/086304 Solicitante OSIVAX Inventor/a LE VERT, Alexandre
The invention relates to immunogenic compositions and their use as a vaccine for the prevention of coronavirus disease in a human subject. More specifically, the invention relates to methods of use of an immunogenic composition in the prevention of coronavirus disease in a human subject in need thereof, said immunogenic composition comprising: a fusion protein comprising (i) a SARS-Cov2 nucleocapsid N antigen and, (ii) a carrier protein comprising a self-assembling polypeptide derived from C4bp oligomerization domain and a positively charged tail.

19.WO/2023/114273METHODS OF TREATING CANCER AND MONITORING ANTI-CANCER IMMUNITY
WO - 22.06.2023
Clasificación Internacional A61K 39/00 Nº de solicitud PCT/US2022/052802 Solicitante ZHANG, Lurong Inventor/a ZHANG, Lurong
The invention relates to induced neoantigen vaccines and a method of using same to treat cancer by enhancing a patient's anti-cancer immunity. The method involves application of an induction radiation to the patient to generate an "in situ vaccine" in vivo, subsequent removal of the tumor, subjecting its cells to a survival pressure for further production of neoantigens in vitro, and processing of the cells to obtain a self-tumor vaccine. The invention provides comprehensive mobilization of individualized anti-cancer active immunity via sequential combination of means of cancer treatments (e.g., radiotherapy, surgery, chemotherapy). Another aspect of the invention relates to an immunoassay protocol to monitor parameters indicative of the cellular and humoral anti-cancer immunity of a patient.

20.WO/2023/116374HERPES ZOSTER VACCINE COMPOSITION
WO - 29.06.2023
Clasificación Internacional A61K 39/25 Nº de solicitud PCT/CN2022/135376 Solicitante SHANGHAI ZERUN BIOTECHNOLOGY CO., LTD. Inventor/a ZHANG, Chao
Provided is a herpes zoster vaccine composition. The composition comprises a varicella-zoster virus antigen and a composite adjuvant, wherein the composite adjuvant comprises a CpG oligodeoxynucleotide, QS-21 and a liposome, and the CpG oligodeoxynucleotide is CpG 7909. The composition can induce a strong antibody reaction and T cell immune response, and is used for preventing varicella-zoster virus infections.

21.WO/2023/115676DENDRITIC CELL CANCER VACCINE AND USE THEREOF
WO - 29.06.2023
Clasificación Internacional C12N 5/0784 Nº de solicitud PCT/CN2022/073141 Solicitante SUZHOU ERSHENG BIOMEDICAL CO., LTD. Inventor/a LIU, Mi
Provided is a dendritic cell cancer vaccine, which is obtained by delivery particles loaded with cell components activating dendritic cells in vitro, wherein the delivery particles are nanoparticles and/or microparticles, the cell components are derived from water-soluble components and/or non-water-soluble components of cancer cells and/or tumor tissue cells, and activation is a process in which the delivery particles loaded with the cell components and the dendritic cells are co-incubated.

22.4198052PEPTIDE UND ANTIGENBINDENDE PROTEINE ZUR VERWENDUNG IN DER IMMUNTHERAPIE GEGEN FIBROLAMELLARES HEPATOZELLULÄRES KARZINOM (FL-HCC) UND ANDERE KREBSARTEN
EP - 21.06.2023
Clasificación Internacional C07K 14/705 Nº de solicitud 21214728 Solicitante UNIV TUEBINGEN MEDIZINISCHE FAKULTAET Inventor/a WALZ JULIANE
The present invention relates to peptides, antigen binding proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer, especially of fibrolamellar hepatocellular carcinoma (FL-HCC). The present invention furthermore relates to tumor-associated T-cell peptide epitopes and recombinant T-cell receptors that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients.

23.WO/2023/121960COMPOSITIONS AND METHODS FOR DELIVERY AND PRODUCTION OF ANTIBODIES USING AN RNA-CONTAINING NANOPARTICLE PLATFORM
WO - 29.06.2023
Clasificación Internacional C07K 16/18 Nº de solicitud PCT/US2022/053132 Solicitante THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE Inventor/a KEDL, Ross
Embodiments of the instant disclosure relate to novel complexes, compositions, and methods for generating and delivering antibodies to induce a pathway in a subject. Other embodiments relate to generating antibodies for treating a health condition or inducing a pathway for inducing a cellular immune response to treat a health condition. In accordance with these embodiments, nanoparticle complexes disclosed herein include antibody-encoding mRNA transcripts, encapsulated into a lipid nanoparticle. In other embodiments, complexes disclosed herein can be administered to a subject in combination with administration of a vaccine to a subject.

24.WO/2023/111182PEPTIDES AND ANTIGEN BINDING PROTEINS FOR USE IN IMMUNOTHERAPY AGAINST FIBROLAMELLAR HEPATOCELLULAR CARCINOMA (FL-HCC) AND OTHER CANCERS
WO - 22.06.2023
Clasificación Internacional C07K 14/705 Nº de solicitud PCT/EP2022/086159 Solicitante EBERHARD KARLS UNIVERSITAET TUEBINGEN MEDIZINISCHE FAKULTAET Inventor/a WALZ, Juliane
The present invention relates to peptides, antigen binding proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer, especially of fibrolamellar hepatocellular carcinoma (FL-HCC). The present invention furthermore relates to tumor-associated T-cell peptide epitopes and recombinant T-cell receptors that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients.

25.4196157ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON GASTROINTESTINALEN ADENOKARZINOMEN DURCH VERÄNDERUNG DER TUMORMIKROUMGEBUNG
EP - 21.06.2023
Clasificación Internacional A61K 39/12 Nº de solicitud 21765592 Solicitante NORDIC SCIENCE GROUP APS Inventor/a UTTENTHAL LARS OTTO
The present invention provides compositions comprising a vaccine against the SARS- CoV-2 virus for promoting an antitumor immune response in a subject with an accessible adenocarcinoma tumor who has previously been exposed to said virus by infection or vaccination, by the direct injection of the composition into the tumor.

26.WO/2023/109979FUSION PROTEIN DISPLAYING SARS-COV-2 S PROTEIN, RECOMBINANT VIRION, AND USE OF FUSION PROTEIN AND RECOMBINANT VIRION

WO - 22.06.2023
Clasificación Internacional Nº de solicitud PCT/CN2023/076443 Solicitante ZHEJIANG DIFFERENCE BIOLOGICAL TECHNOLOGY CO., LTD Inventor/a CHEN, Ruiting
Provided in the present invention are a fusion protein displaying a SARS-COV-2 S protein, a recombinant virion, and the use of the fusion protein and the recombinant virion, which belong to the technical field of biological products. Provided in the present invention are a fusion gene expressing a SARS-COV-2 S protein, and a fusion protein, wherein the fusion gene or fusion protein contains the sequence of an extracellular domain of a SARS-COV-2 S protein and the sequences of a transmembrane domain and an intracellular domain of an Avian paramyxovirus (APMV) F protein. Meanwhile, a recombinant NDV virus containing the sequences has a strong ability to neutralize an antibody. It can be seen that the fusion gene or protein formed by means of fusing a sequence encoding an extracellular domain of an S protein with sequences encoding a transmembrane domain and an intracellular domain of an APMV (excluding NDV) F protein has great potential to be an excellent candidate antigen for a SARS-COV-2 vaccine.

27.WO/2023/121131CORONAVIRUS VACCINE
WO - 29.06.2023
Clasificación Internacional C12N 15/63 Nº de solicitud PCT/KR2022/020354 Solicitante HANMI PHARM. CO., LTD. Inventor/a HAN, Seung Su
Provided are: a non-natural 5'-untranslated region and 3'-untranslated region nucleotide; and a use thereof.

28.WO/2023/121050COMPOSITION FOR PREVENTING OR TREATING ISCHEMIA-REPERFUSION INJURY AND USE THEREOF
WO - 29.06.2023
Clasificación Internacional A61K 48/00 Nº de solicitud PCT/KR2022/019524 Solicitante NA VACCINE INSTITUTE Inventor/a KIM, Dong Ho
Provided are a composition for preventing or treating ischemia-reperfusion injury and a use thereof.

29.WO/2023/109535ANTI-MAREK'S DISEASE VIRUS MONOCLONAL ANTIBODY, HYBRIDOMA CELL STRAIN THEREOF, AND USE OF ANTI-MAREK'S DISEASE VIRUS MONOCLONAL ANTIBODY IN DETECTION KIT
WO - 22.06.2023
Clasificación Internacional C07K 16/08 Nº de solicitud PCT/CN2022/136408 Solicitante SHANGHAI VETERINARY RESEARCH INSTITUTE, CHINESE ACADEMY OF AGRICULTURAL SCIENCE (CHINA ANIMAL HEALTH AND EPIDEMIOLOGY CENTER SHANGHAI BRANCH) Inventor/a LI, Zejun
Disclosed in the present invention is an anti-Marek's disease virus monoclonal antibody. Further disclosed in the present invention are a detection kit for Marek's virus antibody and the use of the monoclonal antibody in the preparation of a product for diagnosing or treating Marek's disease. A blocking ELISA kit for detecting the Marek's virus antibody prepared by using the anti-Marek's virus monoclonal antibody in the present invention has strong specificity and high sensitivity, and has good application prospects in epidemiological investigation of Marek's virus, vaccine immune efficacy evaluation and diagnosis of Marek's disease.

30.4197551ADOPTIVER ZELLTRANSFER UND ONKOLYTISCHE VIRUS-KOMBINATIONSTHERAPIE
EP - 21.06.2023
Clasificación Internacional A61K 39/00 Nº de solicitud 22208589 Solicitante UNIV MCMASTER Inventor/a WAN YONGHONG
The present invention describes a method for treating cancer comprising adoptive transfer of tumor antigen specific CD8+ T cells and an oncolytic virus vaccine targeting the same antigen.

31.4196155LYOPHILISIERTE LEBENDE BORDETELLA-IMPFSTOFFE

EP - 21.06.2023
Clasificación Internacional A61K 39/10 Nº de solicitud 21856843 Solicitante ILIAD BIOTECHNOLOGIES LLC Inventor/a THALEN MARCEL
Formulations of lyophilized *Bordetella* bacteria which are stable for at least two years when stored at temperatures between -20° and 22.5°C, and which exhibit sufficient bacterial viability and potency to be used as a live vaccine are made by harvesting *Bordetella* bacteria from a culture at an OD600 between 0.4 and 1.6; mixing the harvested *Bordetella* bacteria with a lyophilization buffer comprising 5-65% by weight a cryoprotectant sugar and having a temperature between 2-35°C, wherein the ratio of harvested *Bordetella* bacteria to lyophilization buffer is between 5:1 and 1:5 by volume; lyophilizing the mixture of the *Bordetella* bacteria and the lyophilization buffer; wherein the hold time between the harvesting and lyophilizing steps is less than 48 hours; and collecting the lyophilized *Bordetella* bacteria.

32.4198043VERFAHREN ZUR HERSTELLUNG EINES DEM INAKTIVIERTEN SARS-COV-2-VIRUS ENTSPRECHENDEN ANTIGENS, DEM INAKTIVIERTEN SARS-COV-2-VIRUS ENTSPRECHENDE ANTIGENZUSAMMENSETZUNG, KITS UND VERWENDUNGEN DAVON
EP - 21.06.2023
Clasificación Internacional C07K 14/165 Nº de solicitud 21786080 Solicitante INST BUTANTAN Inventor/a OLIVEIRA RICARDO DAS NEVES
The present invention relates to techniques and processes for the production, purification, inactivation and analysis of SARS-CoV-2. The present invention refers to the process to produce an antigen, corresponding to SARS-COV-2 virus, inactivated by gamma irradiation. The process to produce an antigen, corresponding to SARS-COV-2 viruses inactivated by gamma irradiation, is to be used in the production of a new vaccine, antigen for the production of hyperimmune plasma in horses for serum therapy, and in different animal species for the production of antibodies/inputs for research and establishment of serodiagnostic techniques. The present invention refers to the antigenic composition in which it comprises the antigen, corresponding to the inactivated SARS-COV-2 virus, and a pharmaceutically acceptable vehicle, excipient, diluent. It also relates to a Process for producing anti-SARS-CoV-2 immunoglobulin using the SARS-COV-2 virus inactivated by gamma irradiation

33.WO/2023/111861PROSTATE CANCER VACCINES AND USES THEREOF
WO - 22.06.2023
Clasificación Internacional A61K 39/00 Nº de solicitud PCT/IB2022/062162 Solicitante JANSSEN BIOTECH, INC. Inventor/a WILKINSON, Patrick
Disclosed herein are methods of treating or preventing prostate cancer in a subject, the methods comprising administering to the subject a treatment regimen comprising two or more vaccines comprising a great ape adenovirus serotype 20 (GAd20) virus that, in turn, comprises a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 1 and one or more vaccines comprising a Modified Vaccinia Ankara (MVA) virus that, in turn, comprises a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 3 to thereby treat or prevent the prostate cancer.

34.WO/2023/122774IMMUNOGENICITY OF A CPG-ADJUVANTED HERPES ZOSTER VACCINE
WO - 29.06.2023
Clasificación Internacional A61K 39/12 Nº de solicitud PCT/US2022/082311 Solicitante DYNAVAX TECHNOLOGIES CORPORATION Inventor/a JANSSEN, Robert S.
The present disclosure relates to methods for increasing cell-mediated immunity against varicella zoster virus (VZV) in a human subject in need thereof by administration of an immunogenic composition comprising effective amounts of a VZV glycoprotein E antigen and an oligonucleotide comprising an unmethylated cytidine-phospho-guanosine (CpG) motif. The immunogenic compositions are suitable for prevention of herpes zoster and/or postherpetic neuralgia.

35.WO/2023/114418IMPLANTABLE SCAFFOLDS FOR IMMUNOTHERAPEUTIC AND OTHER USES
WO - 22.06.2023
Clasificación Internacional A61K 39/12 Nº de solicitud PCT/US2022/053040 Solicitante THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Inventor/a HASANI-SADRABADI, Mohammad Mahdi
An implantable or injectable scaffold comprising an antigen, a T memory cell inducer, and other optional components is provided for use in enhancing the immune response to the antigen, in particular for subjects who are elderly, immunosenescent and/or immunocompromised, or undergoing cancer therapy. Coronavirus SARS-CoV-2 has caused millions of confirmed cases and hundreds of thousands of deaths. However, there is no effective drug treatment, and vaccine is in great need to control the spread of such highly infectious virus.

36.WO/2023/111728PÉPTIDOS INMUNOGÉNICOS CONTRA EL VIRUS DISTEMPER CANINO (CDV)
WO - 22.06.2023
Clasificación Internacional A61K 39/175 Nº de solicitud PCT/IB2022/061236 Solicitante UNIVERSIDAD COOPERATIVA DE COLOMBIA Inventor/a RENDON MARÍN, Santiago
El presente desarrollo se refiere a péptidos inmunogénicos contra el Virus Distemper Canino (CDV) que tienen la secuencia X_1-X_2-X_3-X_4-X_3-X_5-X_6-X_7-X_8, diseñados mediante herramientas computacionales y composiciones inmunogénicas que comprenden dichos péptidos, útiles como una alternativa de vacuna universal para prevenir el contagio por CDV en fauna silvestre y doméstica.

37.4023755KUNSTIGE NUKLEINSYREMOLEKYLER TIL FORBEDRET PROTEINUDTRYKKELSE
DK - 19.06.2023
Clasificación Internacional C12N 15/67 Nº de solicitud 21209125 Solicitante CureVac SE Inventor/a Schlake, Thomas
The invention relates to an artificial nucleic acid molecule comprising an open reading frame and a 3'-UTR comprising at least one poly(A) sequence or a polyadenylation signal. The invention further relates to a vector comprising the artificial nucleic acid molecule comprising an open reading frame and a 3'-UTR comprising at least one poly(A) sequence or a polyadenylation signal, to a cell comprising the artificial nucleic acid molecule or the vector, to a pharmaceutical composition comprising the artificial nucleic acid molecule or the vector and to a kit comprising the artificial nucleic acid molecule, the vector and/or the pharmaceutical composition. The invention also relates to a method for increasing protein production from an artificial nucleic acid molecule and to the use of a 3'-UTR for a method for increasing protein production from an artificial nucleic acid molecule. Moreover, the invention concerns the use of the artificial nucleic acid molecule, the vector, the kit or the pharmaceutical composition as a medicament, as a vaccine or in gene therapy.

38.4196160[SARS-COV-)-2-VIRUS-ÄHNLICHER PARTIKEL IMPFSTOFF: ZUSAMMENSETZUNGEN, ABGABESTRATEGIEN, VERFAHREN UND VERWENDUNGEN
EP - 21.06.2023
Clasificación Internacional A61K 39/215 Nº de solicitud 21858993 Solicitante TECHNOVAX INC Inventor/a GALARZA JOSE M
The present application relates to SARS-CoV-2 virus-like particles (VLP) and related plasmids, compositions, and methods. The VLP can comprise a modified spike glycoprotein, a matrix protein, a nucleoprotein N and an envelope protein of SARS-CoV-2, where the modified spike glycoprotein comprises an SI domain and an S2 domain, and includes one or more modifications. These modifications can include: linking the SI and S2 domains via generation of disulfides bonds between the SI and S2 domains; linking intra-polypeptide and inter-polypeptide S2 helices of the S2 domain; and substitution of one or more non-cysteine residues with a cysteine residue to generate one or more disulfide bonds. The

modifications can stabilize a prefusion conformation of the spike glycoprotein and prohibit a transition to a post-fusion structure.

39.4196158SALMONELLA-IMPFSTOFF ZUR BEHANDLUNG DES CORONAVIRUS
EP - 21.06.2023
Clasificación Internacional A61K 39/12 Nº de solicitud 21769894 Solicitante UNIV WUERZBURG J MAXIMILIANS Inventor/a RUDEL THOMAS
The present invention provides live-attenuated bacterium of the genus Salmonella comprising a recombinant plasmid encoding a fusion protein, wherein the fusion protein comprises a coronavirus antigen and an adjuvant peptide.

40.WO/2023/121483IMMUNOSTIMULATORY COMPOSITIONS
WO - 29.06.2023
Clasificación Internacional A61K 39/39 Nº de solicitud PCT/NZ2022/050178 Solicitante VICTORIA LINK LIMITED Inventor/a PAINTER, Gavin Frank
The present application is directed to immunomodulatory compositions comprising invariant NKT cell (iNKT cell) agonist compounds that induce expansion of tissue resident memory T-cells (Trm Cells) in combination with an immune stimulator agent that enhances an immune response to a target antigen or a polynucleotide encoding the immune stimulator. The iNKT agonists are a-GalCer analogue compounds modified at the 6 position of the galactose ring. The immune stimulator is an antigen or an mRNA encoding an antigen to create a vaccine formulation. These combinations are used in the treatment of infection or cancer in a subject, or to enrich the number of Trm cells in the liver of a subject.

41.WO/2023/111592RNA CONSTRUCT
WO - 22.06.2023
Clasificación Internacional C12N 15/86 Nº de solicitud PCT/GB2022/053275 Solicitante IMPERIAL COLLEGE INNOVATIONS LIMITED Inventor/a MCKAY, Paul
The invention relates to RNA constructs, and particularly, although not exclusively, to mRNA constructs and saRNA replicons and to nucleic acids and expression vectors encoding such RNA constructs. The invention extends to the use of such RNA constructs in therapy, for example in treating diseases and/or in vaccine delivery. The invention extends to pharmaceutical compositions comprising such RNA constructs, and methods and uses thereof.

42.WO/2023/114727BACTERIOPHAGE LAMBDA-VACCINE SYSTEM
WO - 22.06.2023
Clasificación Internacional C07K 14/005 Nº de solicitud PCT/US2022/081383 Solicitante THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Inventor/a ADHYA, Sankar L.
Bacteriophage λ are disclosed herein that include a head, a tail, and a lambda genome comprising a nucleic acid sequence encoding a fusion protein comprising a D protein linked to heterologous antigen, wherein the nucleic acid sequence is inserted into a native *gene D* locus adjacent to *gene E*, in the lambda genome, and wherein expression of the fusion protein results in the head of the bacteriophage λ comprising the fusion protein. Host bacterial cells also disclosed herein that are infected with the bacteriophage λ. In addition, immunogenic compositions are disclosed that include an effective amount of the bacteriophage λ. Methods also are disclosed for inducing an immune response to the heterologous antigen in a subject. Furthermore, methods are disclosed for preparing these bacteriophage λ.

43.WO/2023/118033VACCINE
WO - 29.06.2023
Clasificación Internacional A61K 39/108 Nº de solicitud PCT/EP2022/086835 Solicitante GLAXOSMITHKLINE BIOLOGICALS SA Inventor/a BRAUN, Martin Edward

The present invention relates to the field of immunogenic compositions and vaccines, their manufacture, host cells which can be used in their manufacture and the use of such immunogenic compositions and vaccines in medicine. More particularly, it relates to Klebsiella pneumoniae O-antigens, conjugates comprising a K. pneumoniae O-antigen, host cells suitable for their production and immunogenic compositions or vaccines containing at least one Klebsiella pneumoniae O-antigen. The present invention particularly relates to a form of Klebsiella pneumoniae O1v1 O-antigen polysaccharide or O1v2 O-antigen polysaccharide which is produced in the absence of a wbbZ gene.

NOTA ACLARATORIA: Las noticias y otras informaciones que aparecen en este boletín provienen de sitios públicos, debidamente referenciados mediante vínculos a Internet que permiten a los lectores acceder a las versiones electrónicas de sus fuentes originales. Hacemos el mayor esfuerzo por verificar de buena fe la objetividad, precisión y certeza de las opiniones, apreciaciones, proyecciones y comentarios que aparecen en sus contenidos, pero este boletín no puede garantizarlos de forma absoluta, ni se hace responsable de los errores u omisiones que pudieran contener. En este sentido, sugerimos a los lectores cautela y los alertamos de que asumen la total responsabilidad en el manejo de dichas informaciones; así como de cualquier daño o perjuicio en que incurran como resultado del uso de estas, tales como la toma de decisiones científicas, comerciales, financieras o de otro tipo.

Edición: Annia Ramos Rodríguez aramos@finlay.edu.cu
Ma. Victoria Guzmán Sánchez mguzman@finlay.edu.cu
Randelys Molina Castro rmolina@finlay.edu.cu
Irina Crespo Molina icrespo@finlay.edu.cu
Yamira Puig Fernández yamipuig@finlay.edu.cu
Rolando Ochoa Azze ochoa@finlay.edu.cu

FINLAY EDICIONES